Document:

Exhibit 10.01

 

[English translation from Portuguese]

 

INOVA BRASIL PROGRAM

Reference No. 0434/08

 

 

CREDIT FACILITY AGREEMENT BY AND BETWEEN 

FINANCIADORA
DE ESTUDOS E PROJETOS – FINEP 

AND AMYRIS BRASIL S/A. 

 

Stamp: FINANCIADORA DE ESTUDOS E 

PROJETOS – FINEP,
AGREEMENT CODE No. 

0|2|10|0520|00

 

Stamp: Registry of Deeds and 

Documents/Campinas, microfilm

1123292

 

By this private instrument, FINANCIADORA DE ESTUDOS E PROJETOS
– FINEP, a state-owned company operated by the Ministry of Science and Technology, with head office in Brasília,
Federal District, and which provides services in this city, at Praia Flamengo 200 – parte, Federal Taxpayer Registration
CNPJ No. 33.749.086/0001-09, hereinafter referred to as FINEP, and AMYRIS BRASIL S.A., a corporation with head office
in the City of Campinas, State of São Paulo, at Rua James Clerk Maxwell, n° 315, CEP 13069-380, Federal Taxpayer Registration
CNPJ No. 09.379.224/0001-20, hereinafter referred to as BORROWER, by their legal representatives:

 

 

 

SECTION ONE PRICE 

 

FINEP hereby extends to BORROWER a credit facility
in the amount of up to six million four hundred and thirty-five thousand Brazilian Reais (R$6,435,000.00) as part of the
global cost of the PROJECT identified in Section Two, in the total amount of

twenty million nine hundred and eighty-one thousand nine hundred
and ninety-nine Brazilian Reais and ninety-one cents (R$20,981,999.91).

 

SECTION TWO PURPOSE 

 

The purpose of the credit facility extended hereunder is to partially
fund expenses incurred to develop the PROJECT “RESEARCH AND DEVELOPMENT OF FERMENTATION PROCESS FOR PILOT PRODUCTION OF SUGARCANEBASED
BIODIESEL”, hereinafter simply referred to as PROJECT (FINEP reference No. 0434/08), pursuant to Resolution No. 0167/10,
issued on May 10, 2010 by FINEP’S Executive Board, in accordance with the Disbursement Scheduled approved by FINEP.

 

SECTION THREE AVAILABILITY OF FUNDS 

 

1. Subject to the financial and budgetary availability of FINEP,
which is subject to the definition of funds for its investments, the credit facility contemplated herein shall be

 

     

    	INOVA BRASIL PROGRAM
	Reference No. 0434/08

    

 

extended in four (4) disbursements, upon compliance with the conditions
established in Section Five, which disbursements shall be available for withdrawal as follows:

 

1st disbursement: one million seven hundred
and fifty-five thousand Brazilian Reais (R$1,755,000.00) after execution hereof;

 

2nd disbursement: one million five hundred
and sixty thousand Brazilian Reais (R$1,560,000.00) one hundred and eighty (180) days after release of the first disbursement;

 

3rd disbursement: one million five hundred
and sixty thousand Brazilian Reais (R$1,560,000.00) one hundred and eighty (180) days after release of the second disbursement;

 

4th disbursement: one million five hundred
and sixty thousand Brazilian Reais (R$1,560,000.00) one hundred and eighty (180) days after release of the third disbursement.

 

		1.	During the period of use of funds, BORROWER agrees to keep a checking account informed to FINEP for release of
the funds obtained hereunder, as provided in Section Five, item 1 of this Agreement.

 

		2.	The disbursements not made within the estimated period shall be automatically rescheduled for the immediate following equivalent
period. Should the late disbursement be reasonably caused by BORROWER for two (2) consecutive periods, a new Disbursement
Schedule shall be approved by FINEP, subject to FINEP’S financial and budgetary availability.

 

		3.	The date of execution hereof shall be deemed the reference date with regard to the periods contemplated in the Disbursement
Schedule.

 

		4.	The installments provided and not completely used within thirty (30) months as of the date of execution hereof shall
be automatically cancelled.

 

5.1. At the request of BORROWER, FINEP may,
at its sole discretion, extend the terms for use of the disbursements or revoke cancellation of any disbursement, provided FINEP
accepts BORROWER’S reasons, which shall be submitted in writing.

 

 

SECTION FOUR CONSIDERATION 

 

BORROWER hereby irrevocably and irreversibly agrees to share
the PROJECT development costs described in Section Two above with proprietary funds in the minimum amount of fourteen million
five hundred and forty-six thousand nine hundred and ninety-nine Brazilian Reais and ninety-one cents (R$14,546,999.91).

 

 

SECTION FIVE 

 

     

    	INOVA BRASIL PROGRAM
	Reference No. 0434/08

    

 

CONDITIONS FOR THE DISBURSEMENT OF FUNDS 

 

1. The first disbursement shall be conditional upon performance
of the following actions, by BORROWER, within up to sixty (60) days as of execution hereof:

 

a) prove transcription of this Agreement in one of the
Registries of Deeds and Documents of the head office of BORROWER;

 

b) inform the checking account for release of the funds;

 

c) present a Debt Clearance Certificate relating to
Social Security and Third-Party Contributions issued by the Federal Revenue Office;

 

d) present an insurance policy covering movable property
(machinery / equipment);

 

1.1. BORROWER’S failure to comply with
the obligations listed above within the agreed term shall result in automatic termination hereof and shelving of the PROJECT.

 

2. The following disbursements shall be conditional upon submission
of the following documents by BORROWER to FINEP:

 

a) statement of the expenses incurred from the funds
previously released by FINEP;

 

b) statement of the use of proprietary funds in the
minimum amount of:

 

i) eleven million one hundred and forty-four thousand
six hundred and fourteen Brazilian Reais and fifty-nine cents (R$11,144,614.59) 

for release of the second disbursement;

 

ii) one million one hundred and thirty-four thousand
and eighty-five cents (handwritten: Brazilian Reais – initialed) (R$1,134,085.00) for release of the
third disbursement;

 

iii) one million one hundred and thirty-four thousand
and eighty-five cents (handwritten: Brazilian Reais – initialed) (R$1,134,085.00) for release of the
fourth disbursement;

 

c) partial report on the progress of the PROJECT;

 

d) Debt Clearance Certificate relating to Social Security
and Third-Party Contributions issued by the Federal Revenue Office;

 

e) bank letters of guarantee in accordance with the
provisions of Section Twelve hereof, in the following amounts:

 

     

    	INOVA BRASIL PROGRAM
	Reference No. 0434/08

    

 

i) For the second disbursement, a bank letter of guarantee in the minimum
amount of one hundred and forty-four thousand two hundred and sixty-six Brazilian Reais and seventy-eight cents (R$144,266.78),
plus charges hereunder, which bank letter of guarantee shall be valid until thirty (30) days after the maturity date of the last
amortization installment; ii) For the third disbursement, a bank letter of guarantee in the minimum amount of one million five
hundred and sixty thousand Brazilian Reais (R$1,560,000.00), plus charges hereunder, which bank letter of guarantee shall be
valid until thirty (30) days after the maturity date of the last amortization installment; iii) For the fourth disbursement, a
bank letter of guarantee in the minimum amount of one million five hundred and sixty thousand Brazilian Reais (R$1,560,000.00),
plus charges hereunder, which bank letter of guarantee shall be valid until thirty (30) days after the maturity date of the last
amortization installment;

 

3. Within up to one hundred and eighty (180) days after the last disbursement, BORROWER
shall provide FINEP with:

 

a) statement of the expenses incurred from the funds previously released
by FINEP;

 

b) statement of the use of proprietary funds – compensation –
in the minimum amount of one million one hundred and thirty-four thousand two hundred and fifteen Brazilian Reais and thirty-two
cents (R$1,134,215.32);

 

c) one (1) copy of the Final Report on the PROJECT, along with an up to 200-word
summary for external disclosure purposes, which shall provide information relating to the results of the PROJECT, and which shall
highlight up to six (6) keywords identifying the contents of these results;

 

		1.	The expense statements mentioned in items 2 and 3 of this Section shall discriminate the expenses incurred with the PROJECT,
identifying the underlying event, the amount and the number of the corresponding tax invoice or similar document.

 

		2.	FINEP shall only release the installments in case it understands that the documents referred to in items 1 and 2 above
are satisfactory.

 

 

SECTION SIX CHARGES 

 

1. For purposes of the provisions hereof, the following terms are defined:

 

a) SPREAD – Percentage amount corresponding to the remuneration of
the invested capital;

 

b) TJLP – Long-Term Interest Rate, as disclosed by the Central Bank
of Brazil;

 

     

    	INOVA BRASIL PROGRAM
	Reference No. 0434/08

    

 

c) REDUCTION FACTOR – Non-capitalized portion
of the TJLP, currently established as six percent (6%) per year;

 

d) CAPITALIZATION FACTOR – Corresponds to the
result of the adjustment to the TJLP at the reduction factor;

 

e) EQUALIZATION – Instrument that allows reduction
of the charges hereunder to be paid by BORROWER to FINEP;

 

f) EQUALIZATION FACTOR – Based on Administrative
Regulation – MCT No. 727, of November 24, 2005 (published in the Brazilian Federal Register on November 25, 2005), it adjusts
the total amount of interest owed under each transaction, including the portion relating to the TJLP and the portion relating to
the SPREAD.

 

g) DEFAULT – For purposes of article 4 of the
Administrative Regulation – MCT No. 727, of November 24, 2005 (published in the Brazilian Federal Register on November 25,
2005), the company that fails to comply with its obligations to FINEP within up to twenty (20) days after the contractual
maturity date relating to each installment of interest and/or amortization is deemed to be in financial default. Two successive
or alternate late payments in the same fiscal year shall result in loss of the fixed interest rate benefit. In addition,
with regard to technical default and for purposes of the aforementioned article, companies that fail to comply with the
contractual obligations and to observe the contractual terms for more than ninety (90) days shall loose the fixed interest rate
benefit.

 

2. The principal amount of the debt shall accrue interest at the rate of five
percent (5%) per year.

 

2.1. The charges contemplated in item 2 result from the deduction of the equalization
factor relating to the TJLP from the charges owed corresponding to the sum of the five percent (5%)-spread per year and the TJLP.

 

2.2. The amount determined in accordance with the provisions of item 2 of this Section
shall be due on a monthly basis during the grace period. During the amortization period, the aforementioned amount shall be due
jointly with the installments of the principal amount and upon termination or liquidation of the Agreement.

 

3. In the event of loss of the fixed interest rate
benefit,a spread of five percent (5%) per year above the TJLP shall be charged, in which case the criterion contemplated
in items I and II below shall apply:

 

I -TJLP in excess of six percent (6%) per year: 

 

 

     

    	INOVA BRASIL PROGRAM
	Reference No. 0434/08

    

 

a) The amount corresponding to the portion of the TJLP in excess
of six percent (6%) per year shall be capitalized on a daily basis and assessed by means of application of the following term of
capitalization to the outstanding balance, taking into consideration all financial events occurred during such period:

 

n/360

 

FC= [1 + TJLP)/1.06], where:

 

FC -Capitalization Factor;

 

TJLP -Long-Term Interest Rate, as disclosed by the Central
Bank of Brazil, expressed in decimals;

 

n – number of days from the date of the financial
event to the date of capitalization, maturity or liquidation of the obligation. Financial event means any and all financial fact
that results or may result in a change in the outstanding balance.

 

The currency URTJ-01 shall be used as operational support for this
term of capitalization. The daily rate shall be obtained by means of application of the FC factor on the rate of the preceding
date, where n=1.

 

b) SPREAD of five percent (5%) per year above the TJLP,
as mentioned in item 3 of this Section, plus the reduction factor (six percent per year – 6%) shall apply to the outstanding
balance on the maturity date of the interests mentioned in item 3.1 below, or on the date of termination or liquidation hereof.
For purposes of daily calculation of interest, the number of days between the date of each financial event and the aforementioned
maturity dates shall be taken into consideration.

 

c) The amount referred to in item I, letter “a”
of this Section, which shall be capitalized and incorporated in the principal amount of the debt, shall be payable simultaneously
to the installments of principal.

 

II -TJLP equal or inferior to six percent (6%) per year: 

 

a) The capitalization factor of the outstanding balance
shall be one (1);

 

b) SPREAD of five percent (5%) per year plus the TJLP
shall apply to the outstanding balance on the maturity date of the interests mentioned in item 3.1 below, or on the date of termination
or liquidation hereof. For purposes of daily calculation of interest, the number of days between the date of each financial event
and the aforementioned maturity dates shall be taken into consideration.

 

3.1. The amount determined in accordance with the provisions
of items I and II of this Section, as the case may be, shall be due on a monthly basis during the grace period. During the amortization
period, the aforementioned amount shall be payable simultaneously to the

 

     

    	INOVA BRASIL PROGRAM
	Reference No. 0434/08

    

 

installments of the principal and upon termination or
liquidation of the Agreement.

 

4. In the event of default or in case the amount offered is not sufficient for liquidation
of at least one installment of the debt, a special account shall be opened with FINEP in the name of BORROWER, where
the amount of the installments in default plus the charges contemplated in the following items shall be recorded as debit. All
payments made by BORROWER shall be accepted as partial payments of the debt. This procedure, however, shall not result in
novation of the debt and may not be claimed as a sufficient reason to suspend or suppress the default or immediate claim to the
obligation, subject to the provision of Section Seven – LOSS OF THE FIXED INTEREST RATE BENEFIT.

 

4.1. A fine of up to ten percent (10%) shall immediately apply to the amount
of the obligations in default. Such fine shall be calculated in accordance with the number of days in default, as explained in
the following table:

 

4.2. The defaulting BORROWER shall also be subject to the payment of interest
on late payment of one percent (1%) per month, levied on the overdue amount, in addition to the fine referred to in
subsection 4.1 above, which shall be calculated per day of delay.

 

	Number of Days in Default 	Fine 
	One (1) 	One percent (1%) 
	Two (2) 	Two percent (1%) 
	Three (3) 	Three percent (3%) 
	Four (4) 	Four percent (4%) 
	Five (5) 	Five percent (5%) 
	Six (6) 	Six percent (6%) 
	Seven (7) 	Seven percent (7%) 
	Eight (8) 	Eight percent (8%) 
	Nine (9) 	Nine percent (9%) 
	Ten (10) 	Ten percent (10%) 

 

4.3. The installments coming due shall be subject to the charges contemplated herein.

 

4.4. Should the entire amount due be immediately claimed, the outstanding balance shall
accrue the amounts contemplated in the preceding subsections of this Section.

 

5. The amount corresponding to one percent (1%) of
the credit facility shall be used to cover inspection and supervision expenses. This percentage shall be applied on the
amount of each disbursement and shall be deducted upon actual release of the corresponding disbursement.

 

6. In the event of any change in the statutory fund
remuneration criteria, the remuneration contemplated herein shall observe the new remuneration criteria relating

 

     

    	INOVA BRASIL PROGRAM
	Reference No. 0434/08

    

 

to such funds that, in addition to preserving the actual value of the transaction, shall
remunerate it at the same preceding levels. In this case, the new criterion shall only be owed as of the date on which FINEP
gives BORROWER written notice of such change.

 

 

SECTION SEVEN LOSS OF THE FIXED INTEREST RATE BENEFIT 

 

1. Any default as defined in Section Six, item 1, letter “g” shall result
in full loss of the fixed interest rate benefit until the end of the term of effectiveness hereof, effective as of
the date of the default, which loss of the fixed interest rate benefit shall relate to the outstanding installments coming due,
so that the outstanding balance shall be recalculated as of that date, upon elimination of the benefit, as provided in Section
Six, item 3.

 

1.1. Loss of the fixed interest rate benefit shall also apply as a
result of a technical and/or financial default hereunder and/or in any other instrument executed by and among BORROWER and
FINEP.

 

 

SECTION EIGHT OUTSTANDING BALANCE 

 

The outstanding balance shall be composed of the sum of the amount of the disbursements
plus the charges established in Section Six.

 

 

SECTION NINE GRACE PERIOD AND AMORTIZATION 

 

		1.	The charges contemplated in Section Six shall be due during the twenty (20)-month grace period, which is the period
from the date of execution hereof and the maturity date of the first amortization installment.

 

		2.	The outstanding balance shall be paid to FINEP in eighty-one (81) monthly and successive installments,
each of which in the amount of the outstanding balance divided by the number of amortization installments coming due. The maturity
date of the first installment shall be July 15, 2012 and the other installments shall be due on the same day of the following months.
The maturity date of the last installment shall be March 15, 2019.

 

		3.	Failure to receive the collection notice shall not exempt BORROWER from the obligation to pay the outstanding installments
on the dates stated herein.

 

		4.	Whenever the maturity date of the principal and charges falls on a Saturday, Sunday or national holiday, including bank holiday,
such amount shall be paid on the first following business day.

 

SECTION TEN OTHER OBLIGATIONS OF BORROWER 

 

     

    	INOVA BRASIL PROGRAM
	Reference No. 0434/08

    

 

In order to use the credit facility and until final payment of the
whole debt resulting therefrom, BORROWER agrees to comply with the following obligations, in addition to other obligations
established elsewhere in this Agreement:

 

a) to answer by mail any request of information sent
by FINEP within up to thirty (30) days as of the date of request, with regard to the progress of the works or the outcome
of the PROJECT, without prejudice to the inspection to be carried out by FINEP;

 

b) to keep for a term of five (5) years, in am exclusive
file available to FINEP, the evidentiary documents relating to the expenses listed in the statements referred to in items
2 and 3 of Section Five, it being understood that FINEP may deduct from the credit facility amount the amounts relating
to expenses that have not been proved, which have been unsatisfactorily proved or which are not allowed. BORROWER shall
submit to FINEP proof of the aforementioned expenses within thirty (30) days as of the request made by FINEP by mail.

 

c) to refrain from obtaining credit facilities or from
performing actions that directly or indirectly result in a reduced ability to make payments without the prior and express consent
of FINEP, except for actions performed in the ordinary course of business;

 

d) to inform FINEP of any event that results
in a reduction in its ability to make payments or in the amount of the guarantees;

 

e) to immediately inform FINEP in writing of
any event that results in the reduction in, insufficiency or impossibility of the guarantee offered, in order for FINEP to
adopt the applicable measures. In this case, BORROWER shall reinforce or substitute the guarantee within thirty (30) days
as of the written notice sent by FINEP by telegram, certified mail or via the Registry of Deeds and Documents, or by means
of a court notice, which shall neither result in novation nor in release of the joint obligors/guarantors.

 

f) to pay with proprietary funds all expenses required
for formalization hereof;

 

g) to grant FINEP full inspection authority concerning
the execution hereof, especially with regard to the use of the funds actually released, but also with regard to the amounts invested
as compensation;

 

h) to grant FINEP all facilities and access required
for analysis of BORROWER’S legal, technical, economic and financial condition, including, at the discretion of FINEP,
to contract audit services;

 

i) to keep FINEP informed of the outcome of
the financed PROJECT, especially with regard to the amount of the investments actually made upon implementation of the FINAL PROJECT,
on the dates established herein or upon request;

 

     

    	INOVA BRASIL PROGRAM
	Reference No. 0434/08

    

 

j) to mention, whenever it announces the PROJECT contemplated
herein, FINEP’S cooperation as lender, including at the place of execution thereof; 

 

k) to prominently display in its establishment and in
all promotion materials resulting from execution of PROJECT, by means of a plate in accordance with the model, dimensions and inscription
informed on FINEP’S website (http://www.finep.gov.br), the text below or other text provided by FINEP:

 

“VENTURE FINANCED BY FINANCIADORA DE ESTUDOS
E PROJETOS – FINEP” 

 

l) to participate in the costs for preparation of the
PROJECT with the additional amounts required for completion thereof;

 

m) to maintain its head office and management in Brazil,
informing FINEP of any change therein, even if within the Brazilian territory;

 

n) to inform FINEP of all changes in its capital
stock and/or corporate structure within ten days after registration thereof with the applicable Commercial Registry or Civil Registry
of Legal Entities;

 

o) to annually send its balance sheet;

 

p) to comply with the provisions of the laws relating
to the Brazilian Environmental Policy, as well as to perform, during the term of effectiveness hereof, any action to avoid or remedy
damages to the environment that may be caused by the financed PROJECT;

 

q) to regularly comply with its obligations to the environmental
authorities during the term of effectiveness hereof.

 

 

SECTION ELEVEN NET AND CLEAR DEBT 

 

BORROWER is required to acknowledge as proof of its debt
all withdrawals, requests, receipts and money orders or similar documents issued or signed by BORROWER, as well as any accounting
entry made by FINEP in this regard, and FINEP is required to acknowledge as proof of its credit all receipts or communications
issued or signed by FINEP with regard to amounts received to the credit of BORROWER, in order to ensure that the
debt is net and clear at all times, including interest and other expenses that shall add to the principal amount of the debt, provided
BORROWER'S right to require verification of this proof and to be refunded for any possible credit.

 

SECTION TWELVE GUARANTEES 

 

1. In order to guarantee the payment of any obligations hereunder,
such as the principal amount, interest, contractual fine and fine, BORROWER hereby provides to FINEP:

 

     

    	INOVA BRASIL PROGRAM
	Reference No. 0434/08

    

 

1.1. A chattel mortgage on the forty-eight (48) chattels
described and identified in EXHIBIT I hereto, free and clear of any judicial or extrajudicial lien.

 

1.1.1. The aforementioned chattels shall remain in the
possession of BORROWER, which hereby agrees to maintain them in a perfect state of conservation, safety and operation, making
the required repairs as requested by FINEP, which may inspect the chattels at any time.

 

1.1.2. The alienation, encumbrance, lease or assignment
of, or change in, the aforementioned chattels without the prior and express consent of FINEP shall be prohibited.

 

1.1.3. BORROWER hereby declares that it has peaceable
and uncontested possession of the chattels, free and clear of any liens or encumbrances, including tax liens.

 

1.2. Three (3) BANK LETTERS OF GUARANTEE in the
amount of each release, plus charges, issued by a financial institution previously approved by FINEP, which hereby agrees
on its behalf and on the best terms of the law, as GUARANTOR and primary obligor and jointly and severally liable with BORROWER,
upon waiver of the benefits contemplated in articles 827 and 333, sole paragraph of the Brazilian Civil Code (Law 10406, of January
10, 2002), on its behalf and on behalf of its successors, until final payment of the debt.

 

1.2.1. In order to comply with the provisions of the
preceding item, BORROWER shall submit to FINEP bank letters of guarantee previously approved by FINEP, the
maturity date of which shall be thirty (30) days after the maturity date of the last installment of the credit facility agreement,
as stated in Section Five, item 2, letter “e” hereof.

 

1.2.2. The bank letters of guarantee shall be an integral
and inseparable part hereof.

 

1.2.3. The guarantees provided under this Section shall
be deemed indivisible with regard to the amount of the debt.

 

3. BORROWER agrees not to perform any action that could reduce
the amount of the guarantee provided hereunder.

 

3.1. BORROWER shall immediately inform FINEP
in writing of the occurrence of any event rendering the guarantees offered hereunder insufficient or unviable, and BORROWER
hereby agrees to reinforce or substitute the guarantees within thirty (30) days as of the notice sent by FINEP by fax,
telegram or certified mail or via the Registry of Deeds and Documents, or by means of a court notice, under penalty of FINEP
being able to terminate this

 

     

    	INOVA BRASIL PROGRAM
	Reference No. 0434/08

    

 

Agreement by operation of law, regardless of any other
warning, notice or judicial or extrajudicial notification.

 

		1.	FINEP may agree with BORROWER on the substitution, reinforcement, release or even waiver of the guarantees offered
hereunder, which shall not result in novation or in the release of the joint obligors or guarantors.

 

		2.	Should FINEP have to foreclose the securities agreed hereunder or in any possible amendment hereto, including the chattel
mortgage, the guarantor(s) or joint obligors, if any, shall remain jointly and severally liable for the outstanding balance, even
after the judicial or extrajudicial sale of the securities, and they hereby agree to settle such outstanding balance on the date
required by FINEP, including in the events of early maturity hereof, regardless of any other judicial or extrajudicial warning
or notice.

 

		3.	The securities shall be covered against all risks by an insurance policy provided by a Brazilian insurance company to which
they may be subject, for an amount that shall never be lower than the appraisal carried out by FINEP, and BORROWER shall
present the corresponding insurance policy before the first disbursement.

 

6.1. The insurance policy shall state that FINEP
is a beneficiary to the insurance, and it shall also provide that the insured may not reserve the right to substitute the beneficiary
without the consent of FINEP.

 

6.2. Within up to thirty (30) days before termination
of the insurance, BORROWER shall provide FINEP with a proof that the insurance of the securities has been renewed
and send FINEP the corresponding renewed policies, the premiums of which shall have been paid.

 

6.3. Should BORROWER fail to comply with the
obligation contemplated in the preceding item, FINEP is hereby authorized to insure the asset in the name and on account
of BORROWER, which hereby appoints FINEP as its representative, with the required powers to take out the insurance,
and it further agrees to pay or reimburse the premiums owed, the amount of which shall be added to the outstanding balance hereof,
for purposes of calculating interest and other charges, provided FINEP’S right to declare the early maturity of the
debt.

 

6.4. In the event of loss, FINEP may, at its
sole discretion, invest the amount of the compensation for payment of the outstanding balance hereunder, wholly or in part, and
any remaining amount shall be reimbursed to BORROWER.

 

6.5. No amendment to the special conditions of the insurance
policies approved by FINEP may be made without the prior written consent of FINEP.

 

6.6. BORROWER further agrees not to perform,
accept or allow any action that could suspend, impair or prevent any insurance taken out by BORROWER or by FINEP.

 

     

    	INOVA BRASIL PROGRAM
	Reference No. 0434/08

    

 

SECTION THIRTEEN SUSPENSION OF DISBURSEMENTS 

 

Should FINEP decide to declare the early maturity of the debt, it may, upon express
notice to BORROWER, suspend disbursement of the funds in view of the noncompliance with any obligation assumed hereunder
or upon occurrence of any of the following events, it being understood that BORROWER shall provide information or cure the
default within at most thirty (30) days:

 

a) use of the borrowed funds for purposes other than agreed or in noncompliance
with the Disbursement Schedule referred to in Section Two;

 

b) late payment of any amount owed to FINEP;

 

c) inaccuracy of information provided to FINEP by BORROWER,
for purposes of obtaining the credit extended hereunder or during performance hereof;

 

d) negligent interruption of the PROJECT;

 

e) other events that, at the discretion of FINEP, cause the compliance
by BORROWER with the obligations assumed hereunder or the achievement of the goals for which the credit has been extended
unsafe or impossible;

 

f) failure to comply with any obligation assumed by BORROWER hereunder;

 

g) in the event of judicial reorganization or agreement with creditors, adjudication
of bankruptcy or protest in respect of any negotiable instrument with regard to BORROWER and/or its guarantor(s), except
in the event of mistaken protest and/or submission of reasonable grounds for the protest.

 

 

SECTION FOURTEEN EARLY MATURITY OF THE DEBT 

 

Failure to comply with any obligation assumed hereunder or occurrence of any of the events
contemplated in the preceding Section, either before or after full disbursement of the amount mentioned in Section One, shall grant
FINEP, regardless of judicial or extrajudicial notice, the right to terminate this Agreement, in which case the whole debt
hereunder shall become immediately due, as calculated in accordance with the provisions of Section Seven hereof.

 

SECTION FIFTEEN CONTRACTUAL FINE 

 

Should FINEP resort to the courts to receive its credit,
BORROWER shall pay ten percent (10%) of the outstanding debt as contractual fine. This fine may not be reduced and it shall
be due together with the principal and ancillary amounts.

 

     

     

    

 

INOVA BRASIL PROGRAM 

Reference No. 0434/08

 

SECTION SIXTEEN FAILURE TO EXERCISE RIGHTS 

 

No late exercise or failure to exercise any rights or powers granted
to FINEP under the law or hereunder and no forbearance of late compliance with the obligations assumed by BORROWER shall
result in novation, and none of these actions may be construed as a waiver of such rights or powers, which may be exercised at
any time at the sole discretion of FINEP.

 

 

SECTION SEVENTEEN PLACE OF PAYMENT 

 

BORROWER shall pay all amounts due hereunder, either relating
to amortization or to the payment of ancillary amounts, at FINEP’S office in the City of Rio de Janeiro, or wherever
informed by FINEP by means of a collection notice, in Brazilian currency or by means of checks drawn to the order of FINEP.

 

 

SECTION EIGHTEEN JURISDICTION 

 

The parties hereby elect the courts of the City of Rio de Janeiro
to resolve any dispute hereunder, provided FINEP’S right to choose the courts of its head office.

 

The pages of this Agreement are initiated by Priscilla Mouta Nunes,
counsel to FINEP, who is enrolled with the Brazilian Bar Association, Rio de Janeiro Chapter, under No. 134.164, upon authorization
of the undersigned legal representatives.

 

IN WITNESS WHEREOF, the parties execute this instrument in two (2)
counterparts of equal contents and form, for one sole effect, together with the undersigned witnesses.

 

Rio de Janeiro, November 10, 2010.

 

By FINANCIADORA DE ESTUDOS E PROJETOS – FINEP 

 

 

	By	/s/ Luis Manuel Rebelo Fernandes 	/s/ Eduardo Moreira da Costa	 
	 	Luis Manuel Rebelo Fernandes 	Eduardo Moreira da Costa 	 
	 	Chief Executive Officer 	Officer 	 
	 	CPF: 	CPF: 	 
	 	ID: 	ID: 	 

 

By BORROWER – AMYRIS BRASIL S/A: 

 

(sgd) (sgd) [illegible] Collier Felipe Moreira
Caram CPF: 218.950.128-80 CPF: 033.724.916-82

 

     

     

    

 

INOVA BRASIL PROGRAM 

Reference No. 0434/08

 

	WITNESSES: 
	/s/ Rômulo Carvalho	/s/ Tiago Ribeiro Mendes
	Name: Rômulo Carvalho 	Tiago Ribeiro Mendes 
	CPF: 	CPF: 

 

 

 

 

 

 

 

 

     

     

    

 

INOVA BRASIL PROGRAM 

Reference No. 0434/08

EXHIBIT I

ASSETS SUBJECT TO CHATTEL MORTGAGE 

 

INOVA
BRASIL PROGRAM

 

 

	Asset 	Brand 	Model 	Series 
	1.	15-L Fermenter 	Tecnal 	Techbio 15 	08080019, 08080016, 08080014, 09010173, 08080015 
	2.	15-L Fermenter 	Tecnal 	Techbio 15 	09060040, 09050040, 09060039, 08080018, 09060039 
	3.	Ultra freezer 	Sanyo 	MDF-U33V 	890122
	4.	Centrifuge 	Sorval 	Evolution RC #728211 	U28Y-421522-VT 
	5.	Image Digitizer 	Kodak 	Gel Logic 1500 	C96173 
	6.	Refrigerated centrifuge 	Eppendorf 	5810R 	5811XM341440 
	7.	Sugar analyzer 	YSI Life Sciences 	7100 MBS 	08G000035 
	8.	Lyophilizer 	Matrin Christ 	Alpha 2-4 LD Plus 	14392, 31115102 
	9.	HPLC -ion chromatograph 	Dionex 	ICS-3000 	061775, 08100804, 08100727, 08100879 
	10.	Gas chromatograph 	Agilent 	7890A 	CN10844150, CN84251033 
	11.	ATAGO Spectropolarimeter 	ATAGO 	AP-300 	082702M 
	12.	Shaker 	Thermo Scientific 	Labline MaxQ 5000 #SHKE5000-7 	1.41408E+12
	13.	300-L Fermenter 	Sartorius 	Biostat D300-DCU 	L04329-1, -2 
	14.	300-L Fermenter 	Sartorius 	Biostat D300-DCU 	L04329-1, -3 
	15.	Hydrogenator 	PARR Instruments 	9003 TRS 	9003T-0811-8795 
	16.	Gas chromatograph 	Agilent 	G3440AX 	CN10923004, USK0085016 
	17.	Continuous centrifuge 	Alfa-laval 	LAPX 404 	9160
	18.	Continuous centrifuge 	Alfa-laval 	DX 203B-24-60 	4174354/2008 
	19.	LPG vertical boilers – 8kgf/cm2 500 kg/h 	Domel 	VSVG 495 -GLP 	81609361, 08169362 
	20.	LPG vertical boilers – 8kgf/cm2 500 kg/h 	Domel 	VSVG 495 -GLP 	81609361, 08169363 

 

Reference No. 0434/08

 

     

     

    

 

INOVA
BRASIL PROGRAM 

Reference No. 0434/08

 

	21.	Centrifuge DX409 	JDF 	DX 409 B34 	4001403
	22.	Frings Shaker 	Frings 	TRG 1000 	1554
	23.	Dechlorine Filter 2,000L/H, Carbon Steel 	Equipar 	-	7611
	24.	Water and Oil Tank 9,000 liters, Stainless Steel 304 	Equipar 	-	7618
	25.	Honey Storage Tank 15,000 Liters, Carbon Steel 	Equipar 	-	7609
	26.	Water Storage Tank 10,000 Liters, Carbon Steel 	Equipar 	-	7610
	27.	Must Storage Tank 3,500 Liters, Stainless Steel 304 	Equipar 	-	7612
	28.	Clarified Must Storage Tank 3,500 Liters, Stainless Steel 	Equipar 	-	7613
	29.	Hybrid Fermentation Tank (SIP) 5,000 Liters, Stainless Steel 304 	Equipar 	-	7615
	30.	Bubble Colum Fermentation Tank (SIP) 5,000 Liters 	Equipar 	-	7616
	31.	Aseptic Must Pressure Vessel (SIP) 7,000 Liters, Stainless Steel 	Equipar 	-	7614
	32.	Pre-Fermentation Pressure Vessel with Shaker (SIP) 4,000 Liters 	Equipar 	-	7617
	33.	Compressor 6.8m3/min Water Cooled 	Equipar 	-	API781184 
	34.	Bearing Structure – Cooling Tower – Amyris Ma 	Equipar 	-	Not applicable 
	35.	Fermenter Access Platform, Stainless Steel 304 	Equipar 	-	Not applicable 
	36.	Electrical protection panel (CMM) and Transformer – Amyris D 	Equipar 	-	Not applicable 
	37.	Water and Oil Tank 600 Liters, Stainless Steel 304 	Equipar 	-	7839
	38.	CIP Tank with Shaker, Heating, Insulation, 2,500 L, A 	Equipar 	-	7625
	39.	CIP Tank with Shaker, 200 L, Stainless Steel 304 – Tag TQ 14 	Equipar 	-	7626
	40.	CIP Tank with Shaker, 200 L, Stainless Steel 304 – Tag TQ 15 	Equipar 	-	7648

 

 

     

     

    

 

	41.	CIP Tank with Shaker, Heating, Insulation, 2,500 L, A 	Equipar 	-	7647
	42.	CIP Tank with Shaker, Heating, Insulation, 2,500 L, A 	Equipar 	-	7646
	43.	FENE Oil Storage Tank 600 Liters, Stainless Steel 304 	Equipar 	-	7621
	44.	Cold Vinasse Tank 1,000 Liters, Stainless Steel 304 	Equipar 	-	7619
	45.	Cold Vinasse Tank 15,000 Liters, Fiberglass 	Equipar 	-	10857
	46.	Cooling Tower 90,000 L/H 	Equipar 	-	0005/08 
	47.	Oil Condenser Pressure Vessel – Exchanging Area 1.0m2 	Equipar 	-	7624
	48.	Compressed Air Pressure Vessel 3,000 Liters, Carbon Steel 	Equipar 	-	OP7627CONFIDENTIAL
TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND,
WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE CONFIDENTIAL MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Exhibit 10.02

MODIFICATION P00003 TO THE TECHNOLOGY INVESTMENT AGREEMENT

 

Between

 

AMYRIS, INC.,

5885 Hollis Street Suite 100

Emeryville, CA 94608

 

And

 

The Defense Advanced Research Projects Agency

675 North Randolph Street

Arlington, VA 22203-2114

 

Concerning

 

Improving the Timeline for Scaling Up Molecules from Proof Of Concept to Market
Reducing Time and Cost

(Mgs TO Kgs)

 

Agreement No.: HR0011-15-3-0001

DARPA Order No.: HR0011621265

	Total Amount of the Agreement:	$	50,721,349
	Total Estimated Government Funding of the Agreement:	$	35,160,011
	Contractor Share Contribution	$	15,551,338
	Funds Obligated:	$	23,324,088
	Funds Obligated by this Modification	$	6,648,707

 

 

	Recipient Identification Number/Codes:	DUNS: 185930182
	 	CAGE: 47QN9
	 	TIN: 55-0856151

 

Authority: 10 U.S.C. § 2371

 

All provisions, terms, and conditions set forth in this Agreement are applicable and
in full force and effect except as specified otherwise herein.

 

	FOR AMYRIS, INC.	 	FOR THE UNITED STATES OF AMERICA, THE DEFENSE ADVANCED RESEARCH PROJECTS AGENCY
	/s/ Joel R. Cherry	 	/s/ Michael S. Mutty
	 	 	 
	Joel R. Cherry, President, R&D	 	
        Michael S. Mutty

        Agreements Officer

        Contracts Management Office

	 	 	 
	6/20/2016	 	6/20/2016
	(Date)	 	(Date)

 

     

     

    

HR0011-15-3-0001

P00003

 

In order to incorporate changes to the Technology Investment Agreement identified below,
replace Attachment 1 Statement of Work with Revision 2, replace Attachment 3 Total Agreement Funding Plan and Payable Milestones
and Corresponding Payment Schedule with Revision 3, replace Attachment 5 List of Intellectual Property Assertions by the Performer
with Revision 1, replace Attachment 6 List of Property Greater than $5,000 with Revision 1, and provide additional incremental
funding, the parties agree to the following changes:

 

1. The Technology Investment Agreement is revised to: 1) revise the Technology Investment
Agreement Table of Contents page to annotate Agreement Revision 3 and page number revisions tied to the changes made in paragraph
1. above and to annotate Attachment 1 - Revision 2, Attachment 3 - Revision 3, Attachment 5 - Revision 1, and Attachment 6 - Revision
1; 2) remove revision identification and incremental funding data from the cover page to Article V, Obligation and Payment, subparagraph
C. previously titled Accounting and Appropriation Data; now titled Agreement Value, Agreement Funding and Accounting and Appropriation
Data; 3) incorporate additional incremental funding; 4) incorporate under Article VII: Patent Rights, subparagraph A. Allocation
of Principal Rights, subparagraph numbering and a new subparagraph 3. to incorporate Flavor and/or Fragrance exclusion language;
and 5) add a new subparagraph (e) to subparagraph B.1 of Article IX: Foreign Access to Technology, in order to add an exception
solely regarding Flavor and/or Fragrance uses. Changes are shown below.

 

Change 1)

 

TABLE OF CONTENTS – Revision 3

 

	ARTICLES	 	PAGE
	 	 	 
	ARTICLE I	Scope of the Agreement	3
	ARTICLE II	Term	7
	ARTICLE III	Management of the Project	10
	ARTICLE IV	Agreement Administration	11
	ARTICLE V	Obligation and Payment	12
	ARTICLE VI	Disputes	16
	ARTICLE VII	Patent Rights	17
	ARTICLE VIII	Data Rights	21
	ARTICLE IX	Foreign Access to Technology	22
	ARTICLE X	Title to and Disposition of Property	23
	ARTICLE XI	Civil Rights Act	24
	ARTICLE XII	Security	24
	ARTICLE XIII	Subcontractors	24
	ARTICLE XIV	Key Personnel	24
	ARTICLE XV	Order of Precedence	25
	ARTICLE XVI	Execution	25
	ARTICLE XVII	Applicable Law	25
	ARTICLE XVIII	Severability	25
	ARTICLE XIX	Data Sharing Plan and Status Reporting	25

 

ATTACHMENTS

 

	ATTACHMENT 1 – Revision 2	Statement of Work
	ATTACHMENT 2	Report Requirements
	ATTACHMENT 3 – Revision 3	Total Agreement Funding Plan and Payable Milestones and Corresponding Payment Schedule
	ATTACHMENT 4	Funding Schedule
	ATTACHMENT 5 – Revision 1	List of Intellectual Property Assertions by the Performer
	ATTACHMENT 6 – Revision 1	List of Property Greater than $5,000
	ATTACHMENT 7	Certifications for Agreement No. HR0011-15-3-0001

 

     

     

    

HR0011-15-3-0001

P00003

 

Change 2) and Change 3)

 

C.       Agreement Value, Agreement Funding and
Accounting and Appropriation Data

 

Agreement Value

 

Total Amount of the Agreement: $50,721,349

Total Estimated Government Funding of the Agreement: $35,160,011

 

Agreement Funding

TIA Award: $ 6,035,686

P00002 $10,639,695

P00003 $ 6,648,707

Total Funds Obligated: $23,324,088

 

Accounting and Appropriation Data

 

TIA Award

CLIN/SLIN/ACRN: 0001/01/AA

LOA: 012199 097 0400 000 N 20152016 D 1320 BLTM66 2015.MBT-02.CORE.A DARPA 255

FUNDING AMOUNT: $6,035,686

 

P00002

CLIN/SLIN/ACRN: 0001/01/AB

LOA: 012199 097 0400 000 N 20162017 D 1320 BLTM66 2016.MBT-02.CORE.A DARPA 255

FUNDING AMOUNT: $10,639,695

 

P00003

CLIN/SLIN/ACRN: 0001/01/AB

LOA: 012199 097 0400 000 N 20162017 D 1320 BLTM66 2016.MBT-02.CORE.A DARPA 255

FUNDING AMOUNT: $6,648,707

 

Change 4)

 

ARTICLE VII: PATENT RIGHTS

 

A.       Allocation
of Principal Rights

 

1. Unless the Performer shall have notified
DARPA (in accordance with subparagraph B.2 below) that the Performer does not intend to retain title, the Performer shall retain
the entire right, title, and interest throughout the world to each Subject Invention consistent with the provisions of this Article
and 35 U.S.C. § 202. With respect to any Subject Invention in which the Performer retains title, the Government shall have
a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced on behalf of the Government the Subject
Invention throughout the world.

 

2. With regard to Inventions made under
this Agreement that are not Subject Inventions, i.e. Inventions relating to genetically modified organisms, strains, or any compounds
or products made by or from such organisms or strains that are conceived or first actually reduced to practice in the performance
of the Program, the Government retains a right to request from Performer a nonexclusive, nontransferable, irrevocable license,
on fair and reasonable terms, to such Inventions to have such Inventions practiced on behalf of the Government throughout the world.
The Government will provide Performer with written notice identifying the specific Invention to which it is requesting such license.
Prior to granting such license, the Parties agree to negotiate in good faith fair and reasonable terms under which the Performer
would be the exclusive supplier/manufacturer to the Government of the desired compound or product under the Government’s
license. Upon agreement of such fair and reasonable terms between the Performer and the Government, the Performer shall grant the
Government the nonexclusive license described

 

     

     

    

HR0011-15-3-0001

P00003

 

above to such identified Inventions. In the event that no agreement is reached between
Performer and Government with regard to said fair and reasonable terms on Performer’s supply/manufacturing rights, Performer
shall nonetheless grant the Government a nonexclusive, nontransferable, irrevocable license, on fair and reasonable terms, to such
Inventions to have such Inventions practiced on behalf of the Government throughout the world. Failure to reach agreement on fair
and reasonable terms will be resolved in accordance with Article VI. Disputes.

 

3. Notwithstanding anything to the contrary in subparagraph A.2
above, the Parties agree that any license to the Government to any Inventions made under this Agreement that are not Subject Inventions
expressly excludes any and all rights to make, have made, use, sell, offer for sale, or import any compound or product as, or in,
a Flavor or Fragrance, unless the Parties reasonably determine that a national security interest requires the Government to use
such compound or product as, or in, a Flavor or Fragrance, in which case subparagraph A.2 will also be applicable to such use.
As used in this paragraph, “Flavor” means an ingredient(s) whose intended or primary functionality (individually or
as part of a blend with auxiliary materials) is to impart, modify, boost or enhance a desirable taste, flavor or sensation, or
to conceal, modify or minimize an undesirable taste, flavor or sensation, in materials designed for consumption (including food,
beverages, drugs, tobacco and any animal feed). As used in this paragraph, “Fragrance” means an ingredient(s) whose
intended or primary functionality (individually or as part of a blend with auxiliary materials) is to impart, modify, boost or
enhance a desirable scent or odor or to conceal, modify or minimize an undesirable scent or odor, in consumer and industrial grade
products.

 

Change 5)

 

ARTICLE IX: FOREIGN ACCESS TO TECHNOLOGY

 

B. 1.(e) a license and transfer of Technology solely to make, have made, use, offer
for sale, sell, or import a compound or product as, or in, a Flavor (as defined in Article VII.A.3) or Fragrance (as defined in
Article VII.A.3).

 

2. Attachment 1 Statement of Work - Revision 2 is issued to remove Subtask F.2.5 (Month
6), modify Subtask F.3.5 (Month 12) and add Subtask F.3.6 (Month 12).

 

3. Attachment 3 Total Agreement Funding Plan and Payable Milestones and Corresponding
Payment Schedule - Revision 3 is issued to move funding associated with the Statement of Work change identified in paragraph 2.
Above and incorporate the incremental funding line of accounting designation in the CLIN/SLIN/ ACRN column, as shown in bold in
the Attachment.

 

4. Attachment 5 List of Intellectual Property Assertions by the Performer is deleted
and replaced with Attachment 5 - Revision 1 in order to incorporate changes in Arzeda Tables 3 and 4; incorporate Agilent Technologies,
Inc. Tables 5 and 6; incorporate Ruprecht-Karls-Universität Heidelberg, Professor Oliver Trapp, and/or Trapp ChemTech Inc.
Tables 7 and 8, as listed below by title:

 

	Table 5 	List of Technical Data and Computer Software of Agilent Technologies, Inc.
	Table 6 	Exemplary, Non-limiting List of Patents and Patent Applications, Pending or Issued as of, September 11, 2015, of Agilent Technologies, Inc.
	Table 7 	List of Technical Data and Computer Software of Ruprecht-Karls-Universität Heidelberg, Professor Oliver Trapp, and/or Trapp ChemTech Inc.
	Table 8 	Exemplary, Non-limiting List of Patents and Patent Applications, Pending or Issued as of, September 11, 2015, of Ruprecht-Karls-Universität Heidelberg, Professor Oliver Trapp, and/or Trapp ChemTech Inc.

 

5. Attachment 6 List of Property Greater than $5,000 is deleted and replaced with Attachment
6 - Revision 1 in order to incorporate the following Modules H, I, and K changes:

 

Delete:

	H	[*	1	$424,530	$424,530
	H	[*	1	$20,258	$20,258

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

     

     

    

HR0011-15-3-0001

P00003

 

	H	[*	1	$33,440	$33,440
	Add:	 	 	 	 
	H	[*	1	$399,344	$399,344
	H	[*	1	$5,411	$5,411
	H	[*	1	$33,848	$33,848
	H	[*	1	$26,919	$26,919
	H	[*	1	$18,456	$18,456
	H	[*	1	$61,923	$61,923
	H	[*	1	$14,690	$14,690
	H	[*	2	$14,358	$28,716
	I	[*	1	$93,000	$93,000
	I	[*	2	$12,050	$24,100
	K	[*	1	$8,477	$8,477

 

 

6. All provisions, terms, and conditions set forth in this Agreement are applicable
and in full force and effect except as specified otherwise herein.

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

 

     

     

    

 

TECHNOLOGY INVESTMENT AGREEMENT

BETWEEN

 

AMYRIS, INC.,

5885 HOLLIS STREET SUITE 100

EMERYVILLE, CALIFORNIA 94608

 

AND

 

THE DEFENSE ADVANCED RESEARCH PROJECTS AGENCY

675 NORTH RANDOLPH STREET

ARLINGTON, VA 22203-2114

 

CONCERNING

 

IMPROVING THE TIMELINE FOR SCALING UP MOLECULES
FROM PROOF OF CONCEPT

TO MARKET REDUCING TIME AND COST

(MGS TO KGS)

 

Agreement No.: HR0011-15-3-0001 – Revision 3

DARPA Order No.: HR0011518718

Total Amount of the Agreement: $50,721,349

Total Estimated Government Funding of the Agreement: $35,160,011

Funds Obligated: See Article V.C

 

Authority: 10 U.S.C. § 2371

 

 

This Agreement is entered into between the United States of America, hereinafter
called the Government, represented by The Defense Advanced Research Projects Agency (DARPA), and AMYRIS, INC., a corporation organized
and existing under the laws of the State of Delaware with its principal place of business at 5885 Hollis Street, Suite 100, Emeryville,
California 94608 pursuant to and under U.S.

Federal law.

 

	FOR AMYRIS, INC	 	FOR THE DEFENSE ADVANCED RESEARCH
PROJECTS AGENCY
	 	 	 
	/s/ Joel R Cherry       6/20/2016	 	/s/ Michael S. Mutty   2016.06.20
	(Signature & Date)	 	(Signature & Date)
	 	 	 
	
        Joel R. Cherry, President R&D
	 	
        Michael S. Mutty

        Agreements Officer

	(Name, Title)	 	(Name, Title)
	 	 	 

 

 

     

    	Agreement HR0011-15-3-0001

    

 

TABLE OF CONTENTS

 

 

	ARTICLES	 	PAGE
	 	 	 
	ARTICLE I	Scope of the Agreement	3
	ARTICLE II	Term	7
	ARTICLE III	Management of the Project	10
	ARTICLE IV	Agreement Administration	11
	ARTICLE V	Obligation and Payment	12
	ARTICLE VI	Disputes	15
	ARTICLE VII	Patent Rights	16
	ARTICLE VIII	Data Rights	19
	ARTICLE IX	Foreign Access to Technology	21
	ARTICLE X	Title to and Disposition of Property	22
	ARTICLE XI	Civil Rights Act	23
	ARTICLE XII	Security	23
	ARTICLE XIII	Subcontractors	23
	ARTICLE XIV	Key Personnel	23
	ARTICLE XV	Order of Precedence	23
	ARTICLE XVI	Execution	23
	ARTICLE XVII	Applicable Law	24
	ARTICLE XVIII	Severability	24
	ARTICLE XIX	Data Sharing Plan and Status Reporting	24

 

ATTACHMENTS

 

	ATTACHMENT 1 – Revision 2	Statement of Work
	ATTACHMENT 2	Report Requirements
	ATTACHMENT 3 – Revision 3	Total Agreement Funding Plan and Payable Milestones and Corresponding Payment Schedule
	ATTACHMENT 4	Funding Schedule
	ATTACHMENT 5 – Revision 1	List of Intellectual Property Assertions by the Performer
	ATTACHMENT 6 – Revision 1	List of Property Greater than $5,000
	ATTACHMENT 7	Certifications for Agreement No. HR0011-15-3-0001

 

 

    	 	2 of 26	 

    	Agreement HR0011-15-3-0001

    

 

ARTICLE I:SCOPE OF THE AGREEMENT

 

A.       Background

 

Performer is a leader in applying synthetic biology technologies
to engineer living organisms into manufacturing platforms that are able to produce a wide variety of target molecules, many of
which are impossible to produce through traditional manufacturing processes. While current technologies are highly advanced, they
suffer from a lack of integration and automation. By focusing on the same principles that made the United States the leaders in
traditional manufacturing, namely standardized engineering and efficiency gains through automation, the Performer seeks, through
funding in this Agreement, to develop a state of the art open bio-fabrication facility that will shorten the scale-up time and
cost by using biology to produce molecules. Many of these molecules are directly relevant to the DoD mission due to their unique
chemical properties that enable their use as fuels, lubricants, anti-fouling agents, antibiotics, and adhesives while also providing
building blocks for novel families of materials. DARPA’s interest in synthetic biology rises from its potential application
to manufacturing. Biological manufacturing is in its infancy and the work required to reduce the time, effort, and cost needed
to develop a new microbe is risky and at odds with the work needed to bring a product to market which is the chief goal of any
company seeking to capitalize on the technology. The Agreement supports research with a long-term perspective that will enable
academic and commercial participants to perform cutting edge research with less effort and cost than ever before. In addition to
producing molecules relevant to the DoD, the commercial opportunities are immense since virtually any molecule made through traditional
manufacturing processes can be replicated using biology as a catalyst. Although engineering cellular factories has been intermittently
successful, the cost and time required for success have been prohibitive. The Performer’s new technological approach will
develop new molecules and materials while at the same time improving efficacy and efficiency. As a result of these improvement,
the United States will reduce production time to under three years and at less than $10M per molecule while simultaneously handling
100 molecules, a 20X improvement. To achieve these innovations, the Performer will focus on technology development addressing metabolic
pathway and enzyme design, strain construction, phenotypic measurements, large-scale data analysis, and strain optimization. To
ensure success, the Performer will complement its expertise in strain engineering by partnering with companies and academic laboratories
that are leaders in their field. Upon the completion of this agreement, the capacity to perform biological engineering will far
surpass current capabilities. The United States will possess state of the art facilities for design and biomanufacturing of existing
and novel molecules and materials.

 

 

 

    	 	3 of 26	 

    	Agreement HR0011-15-3-0001

    

 

B.       Definitions

 

Affiliate:means, with respect to an entity, any person or entity
that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with such
first entity. For purposes of this definition, “control”, “controlled by”, and “under common control
with” mean (i) the possession, directly or indirectly, of the power to direct the management or policies of an entity, whether
through the ownership of voting securities, by contract relating to voting rights or corporate governance, or otherwise or (ii)
the ownership, directly or indirectly, of more than fifty percent (50%) of the voting securities or other ownership interest of
an entity.

 

Agreement:  The body of this Agreement and Attachments 1 – 7,
which are expressly incorporated in and made a part of the Agreement.

 

Collaborators:  A third party in a contractual arrangement with the
Performer or with a Subcontractor, whether executed before or after the Effective Date, under which arrangement the Performer or
a Subcontractor has agreed to jointly research, develop and/or commercialize a technology or product with such third party and
has an “active role” in such arrangement. For the avoidance of doubt, an “active role” by the Performer
or a Subcontractor is a contractual relationship (1) that involves more than the mere transfer of intellectual property and (2)
where the Performer or a Subcontractor has a significant participation in decision making and/or funding of the activities.

 

Data:  Recorded information, regardless of form or method of recording, which
includes but is not limited to, scientific or technical data, software, trade secrets, and mask works, in each case developed or
generated by the Performer or its Subcontractors in performing the Program under this Agreement. The term “Data” does
not include financial, administrative, cost, pricing or management information.

 

Effective Date: means November 1, 2015.

 

Foreign Firm or Institution:  A firm or institution organized or existing
under the laws of a country other than the United States, its territories, or possessions. The term includes, for purposes of this
Agreement, any agency or instrumentality of a foreign government; and firms, institutions or business organizations which are owned
or substantially controlled by foreign governments, firms, institutions, or individuals.

 

Government:  The United States of America, as represented by DARPA.

 

Government Purpose Rights:  The rights to use, duplicate, or disclose
Data, in whole or in part and in any manner, for Government Purposes only, and to have or permit others to do so for Government
Purposes only.

 

Government Purpose:  Any activity in which the Government is a party,
including cooperative agreements with international or multi-national defense organizations or sales or transfers by the Government
to foreign governments or international organizations. Government Purposes include competitive procurement, but do not include
the rights to use, modify, reproduce, release, perform, display, or disclose Data for commercial purposes or authorize others to
do so.

 

Invention:  Any invention or discovery which is or may be patentable or otherwise
protectable under Title 35 of the United States Code.

 

Know-How:  All information including, but not limited to discoveries,
formulas, materials, Inventions, processes, ideas, approaches, concepts, techniques, methods, software, programs, documentation,
procedures, firmware, hardware, technical data, specifications, devices, apparatus and machines.

 

    	 	4 of 26	 

    	Agreement HR0011-15-3-0001

    

 

Limited Rights:  The rights to use, modify, reproduce, release, perform,
display, or disclose Data, in whole or in part, within the Government. The Government may not, without the written permission of
the Party asserting limited rights, release or disclose applicable Data outside the Government, use the applicable Data for manufacture,
or authorize the applicable Data to be used by another party, except that the Government may
reproduce, release, or disclose such Data or authorize the use or reproduction of the applicable Data by persons outside the Government
if -

 

		(i)	The reproduction, release, disclosure , or use is:

		A.	Necessary for emergency repair and overhaul; or

		B.	A release or disclosure to

1. A covered Government support contractor in performance
of its covered Government support contract for use, modification, reproduction, performance, display or release or disclosure to
a person authorized to receive Limited Rights Data; or

2. A foreign government, of such Data other than detailed
manufacturing or process Data, when use of such Data by the foreign government is in the interest of the Government and is required
for evaluational or informational purposes;

		(ii)	The recipient of the applicable Data is subject to a prohibition on the further reproduction, release, disclosure, or use of
the Data; and

		(iii)	The Performer, or its subcontractor asserting the restriction is notified of such reproduction, release, disclosure, or use.

 

Made:  Relates to any Invention means the conception or first actual
reduction to practice of such Invention.

 

Parties: The Government (represented by DARPA) and the Performer.

 

Payable Milestone: A Program-related task or tasks identified in Attachment 3
for which a corresponding payment (also identified in Attachment 3) will be made by the Government to the Performer upon the Government’s
verification, in accordance with this Agreement, that the Performer (or a Subcontractor) accomplished such task(s).

 

Performer:  AMYRIS, INC. a corporation organized and existing under the laws of
the State of

Delaware with its principal place of business at 5885 Hollis Street, Suite 100, Emeryville,
California

94608

 

Practical Application:  To manufacture, in the case of a composition
of product, to practice, in the case of a process or method, or to operate, in the case of a machine or system; and, in each case,
under such conditions as to establish that the Subject Invention is capable of being utilized and that its benefits are, to the
extent permitted by law or Government regulations, available to the public on reasonable terms. For the avoidance of doubt, the
Parties acknowledge that “Practical Application” under this Agreement may not include actual commercialization of Subject
Invention(s) hereunder because such Subject Invention(s) are likely to be Tools (e.g., it is envisioned that the Tools resulting
from the research carried out under this Agreement will later – outside of this Agreement - be used by the Performer and
its Subcontractors to develop commercial products).

 

Program: Research and development being conducted by the Performer
and its Subcontractors under this Agreement, as set forth in Article I, paragraph C and in Attachment 1, Statement of Work.

 

Property:  Any tangible personal property other than property actually
consumed during the execution of work under this Agreement.

 

    	 	5 of 26	 

    	Agreement HR0011-15-3-0001

    

 

Subcontractor: Those persons or entities that, per a written agreement
with the Performer, will perform certain of the Payable Milestones. As of the date of this Agreement, the Subcontractors consist
of Agilent Technologies, Inc., Arzeda Corporation, m2p-labs GmbH, Ruprecht-Karls-Universität Heidelberg, and Bruker Corporation.

 

Subject Invention:  Any Invention conceived or first actually reduced
to practice in the performance of the Program under this Agreement that is capable of use as a Tool for making or altering a genetically
modified organism; provided however, any Inventions, regardless when conceived or reduced to practice, covering a genetically modified
organism, a strain, or any compound or product made by or from an organism or strain shall not be considered “Subject Inventions”
hereunder. For the avoidance of doubt, no Inventions conceived or reduced to practice prior to the Effective Date, excluding subject
inventions conceived or first actually reduced to practice under the Amyris Living Foundries TIA HR0011-12-3-0006, shall be considered
performed “under this Agreement.”

 

Technology:  Discoveries, innovations, Know-How and Inventions, whether
patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership
accrue, including, but not limited to, patents, trade secrets, maskworks, and copyrights, developed under this Agreement.

 

Term: has the meaning set forth in Article II, paragraph A.

 

Tools: Software, analytical methods, standard operating procedures,
and workflow processes.

 

Unlimited Rights:  Rights to use, duplicate, release, or disclose Data,
in whole or in part, in any manner and for any purposes whatsoever, and to have or permit others to do so.

 

C.       Scope

 

1.       The Performer
shall perform the Program, which is intended to build an open BioFab that shortens the timeline for scaling up molecules from proof
of concept to market to two to three years, reduces the cost of such development to less than $10 million per molecule, and simultaneously
handles a hundred molecules. Success will be demonstrated by delivering 1 kg of material for 10 molecules generated by an integrated
pipeline that enables the biological production of metric tons of any subsequent molecule in two to three years. The Program shall
be carried out in accordance with the Statement of Work incorporated in this Agreement as Attachment 1. The Performer shall submit
or otherwise provide all documentation required by Attachment 2, Report Requirements.

 

2.       The Performer
shall be paid for each Payable Milestone accomplished in accordance with the Schedule of Payments and Payable Milestones set forth
in Attachment 3 and the procedures of Article V. The Schedule of Payments and Payable Milestones set forth in Attachment 3 may
be revised or updated in accordance with Article III, subject to mutual agreement of the Parties.

 

3.       The Government and the
Performer estimate that the Statement of Work for this Agreement can only be accomplished with the Performer’s provision
during the Term of the “Performer Contribution”, as detailed in the Total Agreement Funding Plan set forth in Attachment
3 and the Funding Schedule set forth in Attachment 4. The Total Agreement Funding Plan and the Funding Schedule may be revised
or updated in accordance with Article III, subject to mutual agreement of the Parties. The Performer intends and, by entering into
this Agreement, undertakes to cause the Performer Contribution to be provided. However, if either the Government or the Performer
is unable to provide its respective funding (in the case of the Government) or the Performer Contribution (in the case of the Performer)
for the Program, the other Party

 

    	 	6 of 26	 

    	Agreement HR0011-15-3-0001

    

 

may reduce its funding or Performer Contribution, whichever is applicable to it, for
the Program by a proportional amount. Throughout the Term, the Parties, through the Performer’s routine reports to the Government,
will monitor the Performer’s satisfaction of the Performer Contribution and will promptly address, in good faith, any divergence
or shortfall in the final Performer Contribution amount anticipated by the Performer (e.g., the Performer purchases Property for
the Program at a price significantly cheaper than what was anticipated when establishing the Performer Contribution) and its effect,
if any, on the Government’s funding obligation under this Agreement.

 

D.       Goals / Objectives

 

1.       The goal of
this Agreement is for the Performer to investigate and build a BioFab that scales up molecules from proof of concept to market
in less time and at less cost, as described under Scope above. The goal is to accomplish this by incorporating radical innovations
into key modules at each stage of the Design-Build-Test-Learn cycle as described in detail Amyris Proposal “Mgs to Kgs”
dated February 3, 2015. The modules will be interdependent and align within an integrated pipeline. The foundation is a set of
measurement technologies with various levels of risk. In addition to new algorithms for pathway prediction, data analysis and hypothesis
generation, the BioFab’s testing and optimization of up to 450 molecules from a large metabolic space will require a paradigm
shift from a high-throughput, single-molecule screening platform to a high throughput, molecule-agnostic screening platform that
is predictive of performance to a large scale. To address the gaps in throughput, quality and scale, a testing platform that utilizes
a tiered approach to promote strains will be developed. Although individual tiers exist in some form at various institutions and
companies (including at the Performer), there is not a single platform that has managed to encompass all of them into a single
pipeline at the proposed scale.

 

2.       The Government
will have continuous involvement with the Performer. The Government will also obtain access to research results and certain rights
in Data and Subject Inventions pursuant to Articles VII and VIII. Government and the Performer are bound to each other by a duty
of good faith and best research effort in achieving the goals of the Program.

 

3.       This Agreement
is an "other transaction" pursuant to 10 U.S.C. § 2371. The Parties agree that the principal purpose of this Agreement
is for the Government to support and stimulate the Performer to provide its best effort in advanced research and technology development
and not for the acquisition of property or services for the direct benefit or use of the Government. The Performer will be paid
a fixed amount for each Payable Milestone accomplished in accordance with the Payable Milestones and Corresponding Payment Schedule
set forth in Attachment 3 and the procedures of Article V. The Parties agree that the amount payable to Performer for an accomplished
Payable Milestone will be unaffected by whether Performer ends up expending more or less effort to accomplish such Payable Milestone
than the Parties assumed would be required to accomplish it. This Agreement is not intended to be, nor shall it be construed as,
by implication or otherwise, a partnership, a corporation, or other business organization.

 

ARTICLE II: TERM

 

A.       Term of this Agreement

 

The Program commences upon the Effective Date and continues
for forty-eight (48) months, unless extended as described in paragraph C below, (the “Term”) and is split into three
development and operational phases described below and depicted in the table:

 

“Dev” – in the first twenty-four months, the initial set of
strain designs and testing will be generated using existing infrastructure and processes, while simultaneously developing the new
technology platforms simultaneously;

 

    	 	7 of 26	 

    	Agreement HR0011-15-3-0001

    

 

“DevOps” – newly developed technology platforms will be transferred
to pipeline operations as part of the beta-testing transition process;

 

“Ops” – once the technology transfer is completed, the new
technologies will be part of standard operations.

 

If all Government funds committed for the Program and the
Performer Contribution are expended prior to the expiration of the Term, the Parties have no obligation to continue performance
of the Program and may elect to cease development at that point.

 

Provisions of this Agreement, which, by their express terms
or by necessary implication, apply for periods of time other than specified herein, shall be given effect, notwithstanding this
Article.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	8 of 26	 

    	Agreement HR0011-15-3-0001

    

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have
been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

 

 

    	 	9 of 26	 

    	Agreement HR0011-15-3-0001

    

 

B.       Termination Provisions

 

Subject to a reasonable determination that the Program will
not produce beneficial results commensurate with the expenditure of resources, either Party may terminate this Agreement by written
notice to the other Party, provided that such written notice is preceded by consultation between the Parties. In the event
of a termination of the Agreement under this paragraph B, it is agreed that disposition of Data shall be in accordance with the
provisions set forth in Article VIII, Data Rights. The Government and the Performer will negotiate in good faith a reasonable and
timely adjustment of all outstanding issues between the Parties as a result of termination under this paragraph B. Failure of the
Parties to agree to a reasonable adjustment will be resolved pursuant to Article VI, Disputes. The Government has no obligation
to pay the Performer beyond the last completed and paid Payable Milestone if the Performer decides to terminate under this paragraph
B. For the avoidance of doubt, any termination under this paragraph B by either Party does not require repayment by the Performer
of any Payable Milestone amounts already received by the Performer.

 

C.       Extending the Term

 

The Parties may extend, by mutual written agreement, the
Term if funding availability and research opportunities reasonably warrant. Any extension shall be formalized through modification
of the Agreement by the DARPA Agreements Officer and the Performer’s Administrator.

 

ARTICLE III: MANAGEMENT OF THE PROJECT 

 

A.       Management and Program Structure

 

The Performer shall be responsible for the overall technical
and program management of the Program, and technical planning and execution shall remain with the Performer. The DARPA Agreements
Officer’s Representative, in consultation with the DARPA Program Manager or DARPA management, shall provide recommendations
to Program developments and technical collaboration and be responsible for the review and verification of the Payable Milestones.

 

B.       Program Management Planning Process

 

Program planning will consist of an Annual Program Plan with inputs
and review from the Performer and DARPA management, containing the detailed schedule of research activities and Payable Milestones.
The Annual Program Plan will consolidate quarterly adjustments in the Program’s research schedule, including revisions/modification
to Payable Milestones.

 

1.       Initial
Program Plan: The Performer will follow the initial program plan that is contained in the Statement of Work, Attachment 1, and
in the Payable Milestones and Corresponding Payment Schedule, Attachment 3.

 

2.       Overall Program Plan Annual
Review

 

(a)       The Performer,
with DARPA Agreements Officer’s Representative review, in consultation with the DARPA Program Manager or DARPA management,
will prepare an overall Annual Program Plan in the last month of each Agreement year (i.e., October). The Annual Program
Plan will be presented and reviewed at an annual site review, to be held within the sixty (60) days of each subsequent Agreement
year, which will be attended by the Performer’s Key Personnel (as defined in Article XIV), the DARPA Agreements Officer’s
Representative, senior DARPA management (as appropriate), and other DARPA program managers and personnel (as appropriate). The
Performer, with DARPA participation and review,

 

    	 	10 of 26	 

    	Agreement HR0011-15-3-0001

    

 

will prepare a final Annual Program Plan following such annual site review
as more fully described in Attachment 2, Report Requirements.

 

(b)       The Annual
Program Plan provides a detailed schedule of the Program’s research activities, commits the Performer to use its best efforts
to meet specific performance objectives, includes forecasted expenditures and describes the Payable Milestones. The Annual Program
Plan will consolidate all prior adjustments in the Program’s research schedule, including revisions/modifications to the
Payable Milestones. Recommendations for changes, revisions or modifications to the Agreement which result from this annual review
process shall be made in accordance with the provisions of Article III, paragraph C.

 

C.        Modifications

 

1.       As a result of
the Parties’ meetings (in person or videoconference) or annual reviews or at any other time during the Term, the Program’s
research progress or results or other changes in circumstances (e.g., availability of required materials or equipment from external
vendors, legal freedom to operate, etc.) may indicate that a change in the Statement of Work and/or the Payable Milestones would
be beneficial to Program’s objectives. Recommendations for modifications, including justifications to support any changes
to the Statement of Work and/or the Payable Milestones, will be documented in a letter and submitted by the Performer to the DARPA
Agreements Officer’s Representative with a copy to the DARPA Agreements Officer. This documentation letter will detail the
technical, chronological, and financial impact of the proposed modification to the Program. The Performer shall approve any Agreement
modification. The Government is not obligated to pay for additional or revised Payable Milestones until the Payable Milestones
and Corresponding Payment Schedule, Attachment 3, is formally revised by the DARPA Agreements Officer and made part of this Agreement.

 

2.       The DARPA Agreements
Officer’s Representative shall be responsible for the review and verification of any recommendations to revise or otherwise
modify the Agreement, the Statement of Work, the Payable Milestones and Corresponding Payment Schedule, or any other proposed changes
to the terms and conditions of this Agreement.

 

3.       For
minor or administrative Agreement modifications (e.g., changes in the paying office or appropriation data, changes to Government
or the Performer’s personnel identified in the Agreement, etc.), no signature is required by the Performer.

 

ARTICLE IV: AGREEMENT ADMINISTRATION

 

Unless otherwise provided in this Agreement, approvals permitted
or required to be made by the Government may be made only by the DARPA Agreements Officer. Administrative and contractual matters
under this Agreement shall be referred to the following representatives of the Parties:

 

A.          
Government Points of Contact:

 

DARPA Agreements Officer:

 

DARPA Program Manager:

 

 

DARPA Agreements Officer’s Representative (AOR):

 

    	 	11 of 26	 

    	Agreement HR0011-15-3-0001

    

 

DARPA Administrative Agreements Officer (AAO):

 

 

DARPA Assistant Director, Program Management (ADPM)

 

 

B.       Performer Points of Contact

 

Administrator:

, Program Manager, R&D,

 

Contracting:

, General Counsel,

 

Program Manager:

, PI,

 

BioAnalytics Group Leader:

, Co-PI,

 

Each Party may change its representatives named in this Article by written notification
to the other Party. The Government will effect the change as stated in Article III, C.3 above.

 

ARTICLE V: OBLIGATION AND PAYMENT A.Obligation

1.       The Government’s
liability to make payments to the Performer is limited to only those funds obligated under the Agreement or by modification to
the Agreement. The Government may obligate funds to the Agreement incrementally.

 

2.       If modification
of a Payable Milestone becomes necessary in performance of this Agreement, pursuant to Article III, paragraph C, the DARPA Agreements
Officer and the Performer’s Administrator shall execute a revised Payable Milestones and Corresponding Payment Schedule consistent
with the then current Annual Program Plan.

 

B.       Payments for Accomplished Payable Milestones

 

1.       The Performer
has, and agrees to maintain, an established accounting system, which complies with Generally Accepted Accounting Principles and
the requirements of this Agreement and shall ensure that appropriate arrangements have been made for receiving, distributing and
accounting for all funding. An acceptable established accounting system is one in which all cash receipts and disbursements are
controlled and documented properly.

 

2.       Once the Performer
accomplishes a Payable Milestone, the Performer may seek payment from the Government of the corresponding payment amount in the
Payable Milestones and Corresponding Payment Schedule in Attachment 3. The Performer shall document the accomplishment of such
Payable Milestone by submitting or otherwise providing the Payable Milestones Report required by Attachment 2, Part F. After written
verification of the accomplishment of such Payable Milestone by the DARPA

 

    	 	12 of 26	 

    	Agreement HR0011-15-3-0001

    

 

Agreements Officer’s Representative and approval by the DARPA Agreements
Officer, the associated invoice will be submitted to the payment office via Wide Area Workflow (“WAWF”), as detailed
in subparagraph B.6 of this Article. If a Payable Milestone is composed of more than one task (e.g., Payable Milestones
2, 6, 7, etc.), all such tasks in such Payable Milestone must be fully accomplished before the Performer may seek payment
for such Payable Milestone. However, if a task in a single task Payable Milestone (or all of the tasks in a multi-task Payable
Milestone) cannot be completed by the applicable Milestone (MS) Month set forth in Attachment 3, the Performer will document such
event in its Monthly Technical Status Report, and the Parties will execute a contract modification to incorporate required changes
in Attachment 3, and in Attachments 1 and 4, as applicable. For clarity, the “MS Month” column set forth in Attachment
3 sets forth the Parties’ good faith estimate of the date by which a Payable Milestone will be accomplished, but it is not
a deadline for accomplishing the applicable Payable Milestone. In addition, missing the MS Month does not prevent the Performer
from subsequently accomplishing the applicable Payable Milestone and has no effect on the corresponding payment amount in Attachment
3 once accomplished.

 

If deemed necessary by the DARPA Agreements Officer, payment
approval for the final Payable Milestone will be made after reconciliation of actual Government funding for the Program with the
actual Performer Contribution amount. While there will be this final Government reconciliation and accounting of the Performer
Contribution amount, the Parties agree that the quarterly accounting of the Performer Contribution, as reported in the quarterly
Business Status Report submitted in accordance with Attachment 2, will not, nor is it necessarily intended or required to, uniformly
or proportionally track or match the estimated schedule of the Performer Contribution set forth in either Attachments 3 or 4.

 

3.       Subject to
change only through written Agreement modification, payment shall be made to the address of the Performer’s Administrator
set forth below.

 

AMYRIS, INC., 5885 Hollis Street, Suite 100, Emeryville, California
94608

 

4.       Payments will
be made by the cognizant Defense Agencies Financial Services office, as indicated below, within thirty (30) calendar days of an
accepted invoice in WAWF. WAWF is a secure web-based system for electronic invoicing, receipt and acceptance. The WAWF application
enables electronic form submission of invoices, government inspection, and acceptance documents in order to support DoD’s
goal of moving to a paperless acquisition process. Authorized DoD users are notified of pending actions by e-mail and are presented
with a collection of documents required to process the contracting or financial action. It uses Public Key Infrastructure (“PKI”)
to electronically bind the digital signature to provide non-reputable proof that the user (electronically) signed the document
with the contents. Benefits include online access and full spectrum view of document status, minimized re-keying and improving
data accuracy, eliminating unmatched disbursements and making all documentation required for payment easily accessible.

 

The Performer is required to utilize the WAWF system when
processing invoices and receiving reports under this Agreement. The Performer shall (i) ensure an Electronic Business Point of
Contact is designated in Central Contractor Registration at http://www.ccr.gov and (ii)
register to use WAWF–RA at the https://wawf.eb.mil site, within ten (10) calendar
days after award of this Agreement. Step by step procedures to register are available at the https://wawf.eb.mil
site. The Performer is directed to use the “2-in-1” format when processing invoices.

 

a.       For the Issue By DoDAAC
enter HR0011

b.For the Admin DoDAAC and Ship To fields, enter S0507A.

c.       For the Service
Acceptor field, enter HR0011, Extension 01.

d.       Leave the Inspect
by DoDAAC, Ship From Code DoDAAC and LPO DoDAAC fields blank unless otherwise directed by the DARPA Agreements Officer or DARPA
Administrative Agreements

 

    	 	13 of 26	 

    	Agreement HR0011-15-3-0001

    

 

Officer.

e.       The following guidance
is provided for invoicing processed under this Agreement through WAWF:

 

•The DARPA Agreements Officer’s Representative identified
at Article IV "Agreement Administration" shall continue to formally inspect and accept the deliverable Payable Milestone
reports. To the maximum extent practicable, the DARPA Agreements Officer’s Representative shall review the Payable Milestone
report(s) and either: 1) provide a written notice of rejection to the Performer which includes feedback regarding deficiencies
requiring correction or 2) written notice of acceptance to the DARPA Administrative Agreements Officer, DARPA Program Manager and
DARPA Agreements Officer.

 

•Acceptance within the WAWF system shall be performed by the
DARPA Agreements Officer upon receipt of a confirmation email, or other form of transmittal, from the DARPA Agreements Officer’s
Representative.

 

•The Performer shall send an email notice to the DARPA Agreements
Officer’s Representative and DARPA Agreements Officer upon submission of an invoice in WAWF (this can be done from within
WAWF).

 

•Payments shall be made by DFAS-CO/WEST (HQ0339)

 

•The Performer agrees, when entering invoices entered in WAWF
to utilize the CLINs associated with each Payable Milestone as delineated at Attachment 3. The description of the CLIN shall include
reference to the associated milestone number along with other necessary descriptive information. The Performer agrees that the
Government may reject invoices not submitted in accordance with this provision.

 

Note for DFAS: The Agreement shall be entered into the DFAS system by CLIN
– Milestone association as delineated at Attachment 3. The Agreement is to be paid out by CLIN – Milestone association.
Payments shall be made using the CLIN (MS)/ACRN association as delineated at Attachment 3.

 

5.       Payee Information:
As identified at Central Contractor Registration.

 

•     Cage Code: 47QN9

•     DUNS: 185930182

•     TIN: 55-0856151

 

6.       Financial Records
and Reports: The Performer shall maintain adequate records to account for accomplishment of all Payable Milestones for which payment
is received by the Performer under this Agreement and shall maintain adequate records to account for the Performer Contribution
provided under this Agreement. Upon completion or termination of this Agreement, whichever occurs earlier, the Performer’s
Administrator shall furnish to the DARPA Agreements Officer a copy of the Final Report required by Attachment 2, Part E. The Performer’s
relevant financial records are subject to examination or audit on behalf of DARPA by the Government for a period not to exceed
three (3) years after expiration or earlier termination of the Term. The DARPA Agreements Officer or designee shall have direct
access to sufficient records and information of the Performer to ensure accomplishment of the Payable Milestones for which payment
was received by the Performer under this Agreement and satisfaction of the Performer Contribution under this Agreement. Such audit,
examination, or access shall be performed during business

 

    	 	14 of 26	 

    	Agreement HR0011-15-3-0001

    

 

hours on business days upon reasonable, prior written notice and shall be subject
to the security requirements of the audited party. For clarity, where the labor component of the Performer Contribution is based
upon a fixed price hourly commercial rate(s) documented in a contract (e.g., GSA Schedule contract), the examination or audit of
the labor component of such costs shall be limited to a review of hours worked and shall not include a review of the rates.

 

C.       Agreement Value, Agreement Funding and
Accounting and Appropriation Data

 

Agreement Value

 

Total Amount of the Agreement: $50,721,349

Total Estimated Government Funding of the Agreement: $35,160,011

 

Agreement Funding

	TIA Award	$ 6,035,686
	P00002	$10,639,695
	P00003	$ 6,648,707
	Total Funds Obligated	$23,324,088

 

 

Accounting and Appropriation Data

 

TiA Award

CLIN/SLIN/ACRN: 0001/01/AA

LOA: 012199 097 0400 000 N 20152016 D 1320 BLTM66 2015.MBT-02.CORE.A DARPA 255

FUNDING AMOUNT: $6,035,686

 

P00002

CLIN/SLIN/ACRN: 0001/01/AB

LOA: 012199 097 0400 000 N 20162017 D 1320 BLTM66 2016.MBT-02.CORE.A DARPA 255

FUNDING AMOUNT: $10,639,695

 

P00003

CLIN/SLIN/ACRN: 0001/01/AB

LOA: 012199 097 0400 000 N 20162017 D 1320 BLTM66 2016.MBT-02.CORE.A DARPA 255

FUNDING AMOUNT: $6,648,707

 

 

 

 

    	 	15 of 26	 

    	Agreement HR0011-15-3-0001

    

 

ARTICLE VI: DISPUTES

 

A.       General

 

The Parties shall communicate with one another in good faith and in a timely
and cooperative manner when raising issues under this Article.

 

B.       Dispute Resolution Procedures

 

1.       Any dispute, disagreement,
or misunderstanding between the Government and the Performer concerning questions of fact or law arising from or in connection
with this Agreement, and, whether or not involving an alleged breach of this Agreement, may be raised only under this Article.

 

2.       Whenever disputes,
disagreements, or misunderstandings arise, the Party aggrieved by such dispute, disagreement, or misunderstanding shall provide
written notice to the other Party involved identifying the matter in dispute and inviting the other Party involved in the dispute
to attempt to resolve the issue(s) involved by discussion and mutual agreement as soon as practicable. If the aggrieved Party does
not provide the notification made under subparagraph B.3 of this Article within three (3) months of becoming aware of the dispute,
disagreement, or misunderstanding, then such dispute, disagreement, or misunderstanding will not constitute the basis for relief
under this Article unless the Director of DARPA in the interests of justice waives this requirement.

 

3.       Failing resolution
by mutual agreement described above, the aggrieved Party shall document the dispute, disagreement, or misunderstanding by notifying
the other Party (through the DARPA Agreements Officer or the Performer’s Administrator, as the case may be) in writing of
the relevant facts, identify unresolved issues, and specify the clarification or remedy sought. Within five (5) business days after
providing such notice to the other Party, the aggrieved Party may, in writing, request a joint decision by the DARPA Senior Procurement
Executive and a senior executive (no lower than Vice President, Legal) appointed by the Performer. The other Party shall submit
a written position on the matter(s) in dispute within thirty (30) calendar days after being notified in writing that a joint decision
has been requested regarding the dispute, disagreement, or misunderstanding. The DARPA Senior Procurement Executive and the Performer’s
senior executive shall conduct a review of the matter(s) in dispute and render a decision in writing within thirty (30) calendar
days of receipt of such other Party’s written position. Any such joint decision is final and binding.

 

4.       In the absence
of a joint decision, upon written request to the Director of DARPA, made within thirty (30) calendar days of the expiration of
the time for a joint decision under subparagraph B.3 above, the dispute, disagreement, or misunderstanding shall be further reviewed.
The Director of DARPA may elect to conduct this review personally or through a designee or jointly with a senior executive (no
lower than Vice President, Legal) appointed by the Performer. Following the review, the Director of DARPA or designee will resolve
the issue(s) and notify the Parties in writing. Such resolution is not subject to further administrative review and, to the extent
permitted by law, shall be final and binding.

 

C.       Limitation of Damages

 

Claims for damages of any nature whatsoever pursued under
this Agreement shall be limited to direct damages only up to the aggregate amount of Government funding disbursed as of the time
the dispute arises. In no event shall the Government be liable for claims for consequential, punitive, special and incidental damages,
claims for lost profits, or other indirect damages.

 

 

 

    	 	16 of 26	 

    	Agreement HR0011-15-3-0001

    

 

ARTICLE VII: PATENT RIGHTS

 

A.       Allocation of Principal Rights

 

1. Unless the Performer shall have notified DARPA (in accordance
with subparagraph B.2 below) that the Performer does not intend to retain title, the Performer shall retain the entire right, title,
and interest throughout the world to each Subject Invention consistent with the provisions of this Article and 35 U.S.C. §
202. With respect to any Subject Invention in which the Performer retains title, the Government shall have a nonexclusive, nontransferable,
irrevocable, paid-up license to practice or have practiced on behalf of the Government the Subject Invention throughout the world.

 

2. With regard to Inventions made under this Agreement that are not
Subject Inventions, i.e. Inventions relating to genetically modified organisms, strains, or any compounds or products made by or
from such organisms or strains that are conceived or first actually reduced to practice in the performance of the Program, the
Government retains a right to request from Performer a nonexclusive, nontransferable, irrevocable license, on fair and reasonable
terms, to such Inventions to have such Inventions practiced on behalf of the Government throughout the world. The Government will
provide Performer with written notice identifying the specific Invention to which it is requesting such license. Prior to granting
such license, the Parties agree to negotiate in good faith fair and reasonable terms under which the Performer would be the exclusive
supplier/manufacturer to the Government of the desired compound or product under the Government’s license. Upon agreement
of such fair and reasonable terms between the Performer and the Government, the Performer shall grant the Government the nonexclusive
license described above to such identified Inventions. In the event that no agreement is reached between Performer and Government
with regard to said fair and reasonable terms on Performer’s supply/manufacturing rights, Performer shall nonetheless grant
the Government a nonexclusive, nontransferable, irrevocable license, on fair and reasonable terms, to such Inventions to have such
Inventions practiced on behalf of the Government throughout the world. Failure to reach agreement on fair and reasonable terms
will be resolved in accordance with Article VI. Disputes.

 

3. Notwithstanding anything to the contrary in subparagraph A.2 above,
the Parties agree that any license to the Government to any Inventions made under this Agreement that are not Subject Inventions
expressly excludes any and all rights to make, have made, use, sell, offer for sale, or import any compound or product as, or in,
a Flavor or Fragrance, unless the Parties reasonably determine that a national security interest requires the Government to use
such compound or product as, or in, a Flavor or Fragrance, in which case subparagraph A.2 will also be applicable to such use.
As used in this paragraph, “Flavor” means an ingredient(s) whose intended or primary functionality (individually or
as part of a blend with auxiliary materials) is to impart, modify, boost or enhance a desirable taste, flavor or sensation, or
to conceal, modify or minimize an undesirable taste, flavor or sensation, in materials designed for consumption (including food,
beverages, drugs, tobacco and any animal feed). As used in this paragraph, “Fragrance” means an ingredient(s) whose
intended or primary functionality (individually or as part of a blend with auxiliary materials) is to impart, modify, boost or
enhance a desirable scent or odor or to conceal, modify or minimize an undesirable scent or odor, in consumer and industrial grade
products.

 

B.       Invention Disclosure, Election
of Title, and Filing of Patent Application

 

1.       The Performer
shall disclose each Subject Invention to DARPA within four (4) months after the inventor discloses it in writing to Performer’s
personnel responsible for patent matters or, in the case of no internal writing from the inventor, within two (2) months after
Performer files a provisional application for it; provided however, that in the event the Performer does not file a provisional
application, Performer shall disclose the Subject Invention to the Government within two (2) months of determining that a particular
set of experiments and or data qualify as a Subject Invention. The disclosure to the Government shall be in the

 

    	 	17 of 26	 

    	Agreement HR0011-15-3-0001

    

 

form of a written report and shall identify the Agreement under which the
Subject Invention was Made and the identity of the inventor(s). It shall be sufficiently complete in technical detail to
convey a clear understanding to the extent known at the time of the disclosure, of the nature, purpose, operation, and the
physical, chemical, biological, or electrical characteristics of the Subject Invention. The disclosure shall also identify
any publication, sale, or public use of the Subject Invention and whether a manuscript describing the Subject Invention has
been submitted for publication and, if so, whether it has been accepted for publication at the time of disclosure. The
Performer shall also submit to the Government an annual listing of Subject Inventions.

 

2.       If the Performer
determines that it does not intend to retain title to any such Subject Invention, the Performer shall notify the Government, in
writing, within eight (8) months of disclosure to DARPA. However, in any case where publication, sale, or public use has initiated
the one (1)-year statutory period wherein valid patent protection can still be obtained in the United States, the period for such
notice may be shortened by DARPA to a date that is no more than sixty (60) calendar days prior to the end of the statutory period.

 

3.       The Performer
shall file its initial patent application on a Subject Invention to which it elects to retain title within one (1) year after election
of title or, if earlier, prior to the end of the statutory period wherein valid patent protection can be obtained in the United
States after a publication, or sale, or public use. The Performer may elect to file patent applications in additional countries
(including the European Patent Office and the Patent Cooperation Treaty) within either: (i) ten (10) months of the corresponding
initial patent application; or (ii) six (6) months from the date permission is granted by the Commissioner of Patents and Trademarks
to file foreign patent applications where such filing has been prohibited by a secrecy order.

 

4.       Requests
for extension of the time for disclosure, election, and filing under Article VII, paragraph B, may, at the discretion of DARPA,
and after considering the position of the Performer, be granted.

 

C.       Conditions When the Government
May Obtain Title

 

Upon DARPA’s written request, the Performer shall convey
title to any Subject Invention to DARPA under any of the following conditions:

 

1.       If the Performer
fails to disclose or elects not to retain title to the Subject Invention within the times specified in paragraph B of this Article;
provided, that DARPA may request title only within sixty (60) calendar days after learning of: (i) the failure of the Performer
to disclose; or (ii) Performer’s election not to retain title, in each case within the specified times.

 

2.       In those countries
in which the Performer fails to file patent applications within the times specified in paragraph B of this Article; provided, that
if the Performer has filed a patent application in a country after the times specified in paragraph B of this Article, but prior
to its receipt of the written request by DARPA, the Performer shall continue to retain title to the Subject Invention in that country;
or

 

3.       In any country
in which the Performer decides not to continue the prosecution of, to pay the maintenance fees on, or defend a reexamination of
or opposition proceedings on, a patent application or patent on a Subject Invention.

 

D.       Minimum Rights to the Performer
and Protection of the Performer’s Right to File

 

1.       The Performer
shall retain a nonexclusive, royalty-free, paid-up license throughout the world in each Subject Invention to which the Government
obtains title under paragraph C of this Article, except if the

 

    	 	18 of 26	 

    	Agreement HR0011-15-3-0001

    

 

Performer fails to disclose the Subject Invention within the times specified
in paragraph B of this Article. The Performer’s license to such Subject Invention extends to the Performer’s Affiliates
and Collaborators, if any, and includes the right to grant sublicenses of the same scope to the extent that the Performer was legally
obligated to do so at the time the Agreement was awarded. The license is transferable only with the approval of DARPA, except as
noted above regarding Affiliates and Collaborators of Performer or when transferred to the successor of that part of the Performer’s
business to which the Subject Invention pertains. DARPA approval for a license transfer requiring DARPA approval shall not be unreasonably
withheld or delayed.

 

2.       The Performer’s
license in subparagraph D.1 of this Article may be revoked or modified by DARPA to the extent necessary to achieve expeditious
Practical Application of the Subject Invention pursuant to an application for an exclusive license submitted consistent with appropriate
provisions at 37 CFR Part 404. This license shall not be revoked in that field of use or the geographical areas in which the Performer
continues to practice the general technology developed hereunder in pursuit of commercial goals, including the goal of making the
products derived from such platforms reasonably accessible to the public.

 

3.       Before revocation
or modification of the Performer’s license in subparagraph D.1 of this Article, DARPA shall furnish the Performer a written
notice of its intention to revoke or modify the license, and the Performer shall be allowed thirty (30) calendar days (or such
other time as may be authorized for good cause shown) after the notice to show cause why the license should not be revoked or modified.

 

E.       Action to Protect the Government’s
Interest

 

1.       The Performer
agrees to execute or to have executed and promptly deliver to DARPA all instruments necessary to: (i) establish or confirm the
rights the Government has throughout the world in those Subject Inventions to which the Performer elects to retain title; and (ii)
convey title to DARPA when requested under paragraph D of this Article and to enable the Government to obtain patent protection
throughout the world in that Subject Invention.

 

2.       The Performer
agrees to require, by written agreement, its employees, other than clerical and non-technical employees, to disclose promptly in
writing to personnel identified as responsible for the administration of patent matters and in a format suggested by the Performer
each Subject Invention Made under this Agreement in order that the Performer can comply with the disclosure provisions of paragraph
B of this Article. The Performer shall instruct employees, through employee agreements or other suitable educational programs,
on the importance of reporting Subject Inventions in sufficient time to permit the filing of patent applications prior to U.S.
or foreign statutory bars.

 

3.       The Performer
shall notify DARPA of any decisions not to continue the prosecution of, pay maintenance fees for, or defend in a reexamination
or opposition proceedings on a Subject Invention patent application or patent, in any country, not less than thirty (30) calendar
days before the expiration of the response period required by the relevant patent office.

 

4.       The Performer
shall include, within the specification of any United States patent application and any patent issuing thereon covering a Subject
Invention, the following statement: “This invention was made with Government support under Agreement HR0011-15-3-0001, awarded
by DARPA. The Government has certain rights in the invention.”

 

F.       Lower Tier Agreements

 

The Performer shall include this Article VII, suitably modified
to identify the Parties and, as applicable, Subcontractors, in all subcontracts or lower tier agreements, regardless of tier, for
experimental,

 

    	 	19 of 26	 

    	Agreement HR0011-15-3-0001

    

 

developmental, or research work under the Program.

 

G.       Reporting on Utilization of Subject
Inventions

 

1.       Pursuant to Attachment
2, the Performer agrees to submit, during the Term, an annual report on the general subject matter research at Performer or its
Collaborators, licensees or assignees in connection with utilization of a Subject Invention or on efforts at obtaining such utilization
that is being made by the Performer or its Collaborators, licensees or assignees. Such reports shall include information regarding
the general fields of potential products where such Subject Inventions may ultimately assist in commercial sales. The Performer
also agrees to provide additional reports as may be requested by DARPA in connection with any march-in proceedings undertaken by
DARPA in accordance with paragraph I of this Article. Consistent with 35 U.S.C. § 202(c) (5), DARPA agrees it shall not disclose
such information to persons outside the Government without permission of the Performer.

 

2.       All required reporting
shall be accomplished, to the extent possible, using the iEdison reporting website: https://s-edison.info.nih.gov/iEdison/.
To the extent any such reporting cannot be carried out by use of i-Edison, reports and communications shall be submitted to the
DARPA Agreements Officer and DARPA Administrative Agreements Officer.

 

H.       Preference for American Industry

 

Notwithstanding any other provision of this clause, the Performer
agrees that it shall not grant to any person the exclusive right to use or sell any Subject Invention in the United States or Canada
unless such person agrees that any product embodying the Subject Invention or produced through the use of the Subject Invention
shall be manufactured substantially in the United States or Canada, except when such rights are in connection with a Collaborator.
However, in individual cases, the requirements for such an agreement beyond what is contemplated herein may be waived by DARPA
upon a showing by the Performer: (1) that reasonable but unsuccessful efforts have been made to grant licenses on similar terms
to potential licensees that would be likely to manufacture substantially in the United States; or (2) that, under the circumstances,
domestic manufacture is not commercially feasible.

 

I.       March-in Rights

 

The Performer agrees that, with respect to any Subject Invention
in which it has retained title, DARPA has the right to require the Performer, an assignee, or exclusive licensee of a Subject Invention
to grant a non-exclusive license to a responsible applicant or applicants, upon terms that are reasonable under the circumstances,
and if the Performer, assignee, or exclusive licensee refuses such a request, DARPA has the right to grant such a license itself
if DARPA determines that:

 

1.       Such action is
necessary because the Performer, assignee, or exclusive licensee has not taken effective steps, consistent with the intent of this
Agreement, to achieve Practical Application of the Subject Invention;

 

2.       Such action is
necessary to alleviate health or safety needs which are not reasonably satisfied by the Performer, assignee, or exclusive licensee;

 

3.       Such action is
necessary to meet requirements for public use and such requirements are not reasonably satisfied by the Performer, assignee, or
exclusive licensee; or

 

4.       Such action is
necessary because the agreement required by paragraph I of this Article has not

 

    	 	20 of 26	 

    	Agreement HR0011-15-3-0001

    

 

been obtained or waived or because a licensee of the exclusive right to use or
sell any Subject Invention in the United States is in breach of such agreement.

 

ARTICLE VIII: DATA RIGHTS

 

A.       Allocation of Principal Rights

 

1.       This Agreement
shall be performed with mixed Government and Performer funding. The Parties agree that in consideration for Government funding,
the Performer intends to reduce to Practical Application Subject Invention(s) developed under this Agreement.

 

2.       The Performer
agrees to retain and maintain in good condition, until two (2) years after completion or termination of this Agreement, all Data
necessary to achieve Practical Application of Subject Invention(s).

 

3.       In the event of
exercise of the Government’s “March-in Rights” as set forth under Article VII or in this subparagraph, the Performer
agrees that, with respect to Data necessary to achieve Practical Application of the applicable Subject Invention(s), the Government
has the right to require the Performer to deliver, within sixty (60) calendar days from the date of the written request and at
no additional cost to the Government, all such Data to the Government in accordance with its reasonable directions if the Government
determines that:

 

(a)       Such action is
necessary because the Performer, assignee, or exclusive licensee has not taken effective steps, consistent with the intent of this
Agreement, to achieve Practical Application of the Subject Invention(s) developed during the performance of this Agreement;

 

(b)       Such action is
necessary to alleviate health or safety needs which are not reasonably satisfied by the Performer, assignee, or exclusive licensee;
or

 

(c)       Such action is
necessary to meet requirements for public use and such requirements are not reasonably satisfied by the Performer, assignee, or
exclusive licensee.

 

4.       With respect to
all Data delivered in the event of the Government’s exercise of its right under this subparagraph A.3, the Government shall
receive Unlimited Rights.

 

5.        With
respect to Data developed, generated or delivered under this Agreement, the Government shall receive Government Purpose Rights.

 

6. Any data or intellectual property developed or generated exclusively
at private expense, either prior to, or outside the scope of, this Agreement, to be utilized or delivered under this Agreement
by the Performer and/or its Subcontractors shall be delivered with restrictions as delineated in the List of Intellectual Property
Assertions provided in Attachment 5. The Performer reserves the right to add to or modify the data or intellectual property identified
in Attachment 5, but agrees that it will not use in the performance of this Agreement any private expense data or intellectual
property until Attachment 5 is modified to reflect such additional data or intellectual property, in a contractual document executed
by the Contracting Officer.

 

B.       Marking of Data

 

Pursuant to paragraph A above, any Data delivered under this
Agreement shall be marked with the following legend:

 

    	 	21 of 26	 

    	Agreement HR0011-15-3-0001

    

 

“Use, duplication, or disclosure is subject to the restrictions
as stated in Agreement HR0011-15-3-0001 between DARPA and Amyris, Inc.”

 

C.       Lower Tier Agreements

 

The Performer shall include this Article, suitably modified
to identify the Parties and, as applicable, Subcontractors, in all subcontracts or lower tier agreements, regardless of tier, for
experimental, developmental, or research work under the Program.

 

 

ARTICLE IX:FOREIGN ACCESS TO TECHNOLOGY

 

This Article shall remain in effect during the Term and for two (2) years thereafter.

 

A.       General

 

The Parties agree that research findings and technology developments
arising under this Agreement may constitute a significant enhancement to the national defense and to the economic vitality of the
United States. Accordingly, access to important technology developments under this Agreement by Foreign Firms or Institutions must
be carefully controlled. The controls contemplated in this Article are in addition to, and are not intended to change or supersede,
the provisions of the International Traffic in Arms Regulation (22 CFR pt. 121 et seq.), the DoD Industrial Security Regulation
(DoD 5220.22-R) and the Department of Commerce Export Regulation (15 CFR pt. 770 et seq.)

 

B.       Restrictions on Sale or Transfer
of Technology to Foreign Firms or Institutions

 

1.       In order to promote
the national security interests of the United States and to effectuate the policies that underlie the regulations cited above,
the procedures stated in subparagraphs B.2 and B.3 below shall apply to any proposed Transfer of Technology. For purposes of this
Article IX, a “Transfer of Technology” means a sale of the Performer or of a Subcontractors, and sales or licensing
of Technology, however, the term “Transfer of Technology” does not include:

 

(a)       sales of products
or components incorporating or produced via a Subject Invention(s), or licenses or sales of any genetically modified organism,
strain, or compound made by or from such an organism, strain, excluding genetically modified organism, strain or compound made
by or from an organism or strain developed under this Program.

 

(b)       licenses of software
or documentation related to sales of products or components described in clause (a), or

 

(c)       a transfer of
Technology to foreign subsidiaries of the Performer for purposes related to this Agreement or to Collaborators, or

 

(d)       a transfer of
Technology to a Foreign Firm or Institution, which is a Subcontractor or an approved source of supply or source for the conduct
of research under this Agreement; provided that such transfer shall be limited to that necessary to allow the Foreign Firm or Institution
to perform its approved role under this Agreement.

 

(e) a license and transfer of Technology solely to make,
have made, use, offer for sale, sell, or import a compound or product as, or in, a Flavor (as defined in Article VII.A.3) or Fragrance
(as defined in Article VII.A.3).

 

    	 	22 of 26	 

    	Agreement HR0011-15-3-0001

    

 

2.       The Performer
shall provide written notice to the DARPA Agreements Officer’s Representative and DARPA Agreements Officer of any proposed
Transfer of Technology to a Foreign Firm or Institution by Performer or a Subcontractor at least sixty (60) calendar days prior
to the proposed date of transfer. Such notice shall cite this Article and shall state specifically what Technology is to be transferred
and the general terms of the transfer. Within thirty (30) calendar days of receipt of the Performer’s written notification,
the DARPA Agreements Officer shall advise the Performer whether it consents to the proposed Transfer. If DARPA determines that
the proposed Transfer of Technology may have adverse consequences to the national security interests of the United States, the
Performer (or, if applicable, a Subcontractor) and DARPA shall jointly endeavor to find alternatives to the proposed Transfer of
Technology which obviate or mitigate potential adverse consequences of the Transfer of Technology but which provide substantially
equivalent benefits to the Performer (or, if applicable, a Subcontractor). In cases where DARPA does not concur or sixty (60) calendar
days after receipt and DARPA provides no decision, the Performer (or, if applicable, Performer on behalf of a Subcontractor) may
utilize the procedures under Article VI, Disputes. No such Transfer shall take place until a decision is rendered.

 

3.       In the event a
Transfer of Technology to a Foreign Firm or Institution which is NOT approved by DARPA takes place, the Performer shall: (a) refund
to DARPA funds paid by DARPA for the development of such unapproved transferred Technology; and (b) the Government shall have a
non-exclusive, nontransferable, irrevocable, paid-up license to practice or have practiced on behalf of the Government such Technology
throughout the world for the Government and any and all other purposes, particularly to effectuate the intent of this Agreement.
Upon request of the Government, the Performer shall provide written confirmation of such licenses.

 

C.       Lower Tier Agreements

 

The Performer shall include this Article, suitably modified
to identify the Parties and, as applicable, Subcontractors, in all subcontracts or lower tier agreements, regardless of tier, for
experimental, developmental, or research work under the Program.

 

 

ARTICLE X: TITLE TO AND DISPOSITION OF PROPERTY

 

A.       Title to Property

 

Title to any items of Property acquired under this Agreement
with an acquisition value of $5,000 or less shall vest in the Performer (and/or its Subcontractors) upon acquisition with no further
obligation of the Parties unless otherwise determined in advance by the DARPA Agreements Officer. The Performer (and/or its Subcontractors)
will acquire Property with an acquisition value greater than $5,000 under this Agreement as set forth in Attachment 6 to this Agreement,
which Property is necessary to further the research and development goals of this Program and is not for the direct benefit of
the Government. Title to this Property shall vest in the Performer (and/or its Subcontractors) upon acquisition. Should any other
item of Property with an acquisition value greater than $5,000 be required during the Program, the Performer shall obtain prior
written approval of the DARPA Agreements Officer, which approval shall not to be unreasonably withheld or delayed. Title to this
later acquired Property shall also vest in the Performer (and/or its Subcontractors) upon acquisition. The Performer (and/or its
Subcontractors) shall be responsible for the maintenance, repair, protection, and preservation of all such Property at its own
expense.

 

B.       Disposition of Property with Value
>$5,000

 

    	 	23 of 26	 

    	Agreement HR0011-15-3-0001

    

 

At the completion or termination of the Term, title to (i)
items of Property set forth in Attachment 6 and (ii) any other items of Property acquired under the Program with an acquisition
value greater than $5,000 shall remain vested with the Performer and, if applicable, its Subcontractors without further obligation
to the Government.

 

 

ARTICLE XI: CIVIL RIGHTS ACT

 

This Agreement is subject to the compliance requirements of
Title VI of the Civil Rights Act of 1964 as amended (42 U.S.C. 2000-d) relating to nondiscrimination in Federally assisted programs.
The Performer has signed a Certifications for Agreement No. HR0011-15-3-0001, a copy of which is attached hereto as Attachment
7, which certifies, among other matters, the Performer’s compliance with the nondiscriminatory provisions of the Act.

 

ARTICLE XII:SECURITY

 

The Government does not anticipate the need for the Performer
(or its Subcontractors) to develop and/or handle classified information in the performance of this Agreement. No DD254 is currently
required for this Agreement.

 

ARTICLE XIII:SUBCONTRACTORS

 

The Performer shall make every effort to satisfy the intent
of competitive bidding of sub-agreements to the maximum extent practical. The Performer may use foreign entities or nationals as
Subcontractors, subject to compliance with the requirements of this Agreement and to the extent otherwise permitted by law.

 

ARTICLE XIV: KEY PERSONNEL

 

A.       The Performer shall notify the DARPA
Agreements Officer in writing prior to making any change in Key Personnel for the Program. The following individuals are designated
as ”Key Personnel” for the purposes of this Agreement:

 

	Name	Role/Title	% Time
	 	Principal Investigator (PI)	100%
	 	Co-PI	100%

 

B.       When replacing any of the Key Personnel
identified above, the Performer must demonstrate that the qualifications of the prospective Key Personnel are acceptable to the
Government as reasonably determined by the Program Manager. Substitution of Key Personnel shall be documented by modification to
the Agreement made in accordance with the procedures outlined in Article III, paragraph C.

 

 

ARTICLE XV: ORDER OF PRECEDENCE

 

In the event of any inconsistency between the terms of this
Agreement and language set forth in the Attachments, the inconsistency shall be resolved by giving precedence in the following
order: (1) the Agreement; and (2) all Attachments to the Agreement.

 

    	 	24 of 26	 

    	Agreement HR0011-15-3-0001

    

 

ARTICLE XVI: EXECUTION

 

This Agreement constitutes the entire agreement of the Parties
with respect to the subject matter hereof and supersedes all prior and contemporaneous agreements, understandings, negotiations
and discussions among the Parties, whether oral or written, with respect to the subject matter hereof. This Agreement may be revised
only by written consent of the Performer and the DARPA Agreements Officer. This Agreement, or modifications thereto, may be executed
in counterparts each of which shall be deemed as original, but all of which taken together shall constitute one and the same instrument.

 

 

ARTICLE XVII: APPLICABLE LAW

 

United States federal law will apply to the construction,
interpretation, and resolution of any disputes arising out of or in connection with this Agreement.

 

ARTICLE XIII: SEVERABILITY

 

In the event that any one or more of the provisions contained
herein shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability
shall not affect any other provisions of this Agreement, but this Agreement shall be construed as if such invalid, illegal or unenforceable
provisions had never been contained herein, unless the deletion of such provision or provisions would result in such a material
change so as to cause completion of the transactions contemplated herein to be unreasonable.

 

ARTICLE XIX: DATA SHARING PLAN AND STATUS REPORTING

 

It is the goal of the Government that its investment in
the tools and capabilities developed under the Program to be multiplied many-fold by adoption and improvement by researchers across
the United States. In order to achieve this vision, the Living Foundries program aims to facilitate interoperability and open the
field to new entrants.

 

The Performer shall make available the Tools developed
under the Program to the broader synthetic biology community by presenting its Program research Data at public meetings, conferences,
and workshops and publishing results in peer-reviewed journal articles. At a minimum, the types of information that will be made
available to the broader synthetic biology community are as discussed below:

 

(i) Data and analysis necessary to evaluate the utility of the Tools
developed under the Program, including standard operating procedures and design specifications enabling others to reconstitute
the equipment, set up, and approaches developed.

 

(ii) Details required for technical evaluation
of the Tools developed under the Program: full protocols, technical drawings of equipment built and specifications met, Data on
accuracy and precision of these systems, and results of procedures performed against large number of samples to investigate the
robustness and readiness of the approaches for broader distribution – providing a trained reader with the information needed
to recapitulate the methods and results described.

 

(iii) The Key Personnel shall be reasonably available
to consult with third parties seeking to replicate the results.

 

The Performer shall include as part of required monthly Technical
Status Reports in Attachment 2 an

 

    	 	25 of 26	 

    	Agreement HR0011-15-3-0001

    

 

on-going status of efforts to develop and/or carry out this Intellectual Property
and Data Sharing plan. Reporting shall include a summary of Data sharing activities that have taken place during the reporting
period, and any Data sharing activities planned to take place within three months of the reporting period.

 

The Performer shall also include as part of required monthly Technical Status Reports
in Attachment 2 a listing of the Performer’s Subject Invention disclosures, Subject Invention patent applications and a brief
discussion summarizing plans, if any, to license the resulting Subject Inventions (e.g., intent and rationale regarding whether
the Performer intends to seek non-exclusive licensing, exclusive licensing for a particular field of use, or exclusive licensing
across the board, etc.).

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	26 of 26	 

    	HR0011-15-3-0001

    

 

Attachment 1

M2K Program

Statement of Work (SOW)

 

References:

		(a)	Amyris Proposal “Mgs to Kgs” (M2K) dated February 3, 2015

 

As detailed in reference (a), the Performer will complete the work set forth
below to achieve the Program Goals / Objectives set forth in Technology Investment Agreement HR0011-15-3-0001.

 

MODULE A: [*]

Task A.1: [*] (, Amyris)

Task Objective: [*]

 

Milestone (Month 3): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Task A.2: [*] (, Amyris)

Task Objective: [*]

 

Milestone (Month 12): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 18): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 24): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 30): [*]

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

    	 	1

    	HR0011-15-3-0001

    

 

[*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 36): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 42): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 48): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

MODULE B: [*]

 

Task B.1: [*] (, Amyris)

Task Objective: [*]

 

Milestone (Month 3): [*]

Deliverables: [*]

 

Milestone (Month 12): [*]

Deliverables: [*]

 

Task B.2: [*] (, Amyris)

Task Objective: [*]

 

Milestone (Month 3): [*]

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

    	 	2

    	HR0011-15-3-0001

    

 

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

 

Milestone (Month 9): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Task B.3: [*] (, Amyris)

Task Objective: [*]

 

Milestone (Month 6): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 9): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 15): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 18): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 21): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 24): [*]

Metrics/Completion Criteria: [*]

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

    	 	3

    	HR0011-15-3-0001

    

 

Deliverables: [*]

 

Milestone (Month 30): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

Milestone (Month 36): [*]

Metrics/Completion Criteria: [*]

 

Task B.4: [*] (, Amyris)

Task Objective: [*]

 

Milestone (Month 3): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 6): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 12): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 18): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 24): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Task B.5: [*] (, Amyris)

Task Objective: [*]

 

Milestone (Month 6): [*]

Metrics/Completion Criteria: [*]

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

    	 	4

    	HR0011-15-3-0001

    

 

Deliverables: [*]

 

Milestone (Month 12): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

Milestone (Month 21): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 24): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 24): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 30): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 30): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 36): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 42): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

 

MODULE C: [*]

 

Task C.1: [*] (, Arzeda).

Task Objective: [*]

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

    	 	5

    	HR0011-15-3-0001

    

 

Milestone (Month 3): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

 

 

Milestone (Month 6): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 9): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 9): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 12): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 24): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Task C.2: [*] (, Arzeda).

Task Objective: [*]

 

Milestone (Month 18): [*]

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

 

    	 	6

    	HR0011-15-3-0001

    

 

[*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

Milestone (Month 24): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (month 30): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 42): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

MODULE D: [*]

 

Task D.1: [*] (, Arzeda)

Task Objective: [*]

 

Milestone (Month 12): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 24): [*]

Metrics/Completion Criteria: [*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

 

    	 	7

    	HR0011-15-3-0001

    

 

Deliverables: [*]

 

 

 

Task D.2: [*] (, Arzeda)

Task Objective: [*]

 

Milestone (Month 6): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 9): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 12): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 15): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 18): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 21): [*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

    	 	8

    	HR0011-15-3-0001

    

 

[*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Task D.3: [*] (, Arzeda)

Task Objective: [*]

 

Milestone (Month 6): [*]

Metrics/Completion Criteria: [*]

Deliverable: [*]

 

Milestone (Month 12): [*]

Metrics/Completion Criteria: [*]

Deliverable: [*]

 

Milestone (Month 18): [*]

Metrics/Completion Criteria: [*]

Deliverable: [*]

 

Task D.4: [*] (, Arzeda)

Task Objective: [*]

 

Milestone (Month 21): [*]

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

    	 	9

    	HR0011-15-3-0001

    

 

[*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 21): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 24): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Task D.5: [*] (, Arzeda).

Task Objective: [*]

 

Milestone (Month 30):  [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 36): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 45): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 48): [*] Metrics/Completion
Criteria: [*]

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

    	 	10

    	HR0011-15-3-0001

    

 

[*]

Deliverable: [*]

 

 

 

 

MODULE E: [*]

 

Task E.1: [*] (, Amyris) 

Task Objective: [*]

 

Milestone (Month 12): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 18): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 24): [*] Metrics/Completion
Criteria: [*]

Deliverables: [*]

 

Task E.2: [*] (, Amyris) 

Task Objective: [*]

 

Milestone (Month 18): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 24): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Task E.3 (Month 24): [*] (, Amyris)

Task Objective: [*]

 

Milestone (Month 18): [*]

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

 

    	 	11

    	HR0011-15-3-0001

    

 

[*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

Milestone (Month 24): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

MODULE F: [*]

 

Task F.1: [*] (, Amyris)

Task Objective: [*]

 

Milestone (Month 3): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Subtask F.1.1 (Month 3): [*]

Subtask F.1.2 (Month 3): [*]

 

Subtask F.1.3 (Month 1): [*]

 

Subtask F.1.4 (Month 3): [*]

 

Task F.2: [*] (, Amyris)

Task Objective: [*]

 

Milestone (Month 6): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Subtask F.2.1 (Month 3): [*]

 

Subtask F.2.2 (Month 3): [*]

 

Subtask F.2.2 (Month 4): [*]

 

Subtask F.2.4 (Month 5): [*]

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

 

    	 	12

    	HR0011-15-3-0001

    

 

[*]

 

Subtask F.2.5 (Month 6): Deleted

 

 

Task F.3: [*] (, Amyris)

Task Objective: [*]

 

Milestone (Month 12): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Subtask F.3.1 (Month 3): [*]

 

Subtask F.3.2 (Month 3): [*]

 

Subtask F.3.2 (Month 4): [*]

 

Subtask F.3.4 (Month 10): [*]

 

Subtask F.3.5 (Month 12): [*]

 

Subtask F.3.6 (Month 12): [*]

 

MODULE G: DELETED

 

MODULE H: [*]

 

Task H.1: [*] (, Agilent)

Task Objective: [*]

 

Milestone (Month 6): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 12): [*]

Metrics/Completion Criteria: [*]

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

    	 	13

    	HR0011-15-3-0001

    

 

Deliverables: [*]

 

Milestone (Month 18): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Subtask H.1.1 (Month 3): [*]

 

Subtask H.1.2 (Month 15): [*]

 

Task H.2: [*] (, Amyris). 

Task Objective: [*]

 

Milestone (Month 6): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 12): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Task H.3: [*] (, Amyris)

Task Objective: [*]

 

Milestone (Month 6): [*]

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

    	 	14

    	HR0011-15-3-0001

    

 

[*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

 

Milestone (Month 12): 1) [*].

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 18) [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 24): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Subtask H.3.1 (Month 1): [*]

 

Task H.4: [*] (, Agilent)

Task Objective: [*]

 

Milestone (Month 6): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 12): [*]

Metrics/Completion Criteria: [*]

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

    	 	15

    	HR0011-15-3-0001

    

 

Deliverables: [*]

 

Milestone (Month 24): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Subtask H.4.1 (Month 18): [*]

 

Task H.5: [*] (, Agilent)

Task Objective: [*]

 

Milestone (Month 6): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 12): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Subtask H.5.1 (Month 2): [*]

 

Task H.6: [*] (, Amyris)

Task Objective: [*]

 

Milestone (Month 12): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 18): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

    	 	16

    	HR0011-15-3-0001

    

 

Milestone (Month 30): [*] 

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

 

MODULE I: [*]

 

Task I.1: [*] (, Univ. of Heidelberg)

Task Objective: [*]

 

Milestone (Month 9): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Subtask I.1.1 (Month 2): [*]

 

Subtask I.1.2 (Month 5): [*]

 

Subtask I.1.3 (month 8): [*]

 

Task I.2: [*] (, Univ. of Heidelberg)

Task Objective: [*]

 

Milestone (month 9): [*]

Metrics/Completion Criteria[*]

Deliverables: [*]

 

Subtask I.2.1 (Month 1): [*]

 

Subtask I.2.2 (Month 5): [*]

 

Subtask I.2.3 (Month 8): [*]

 

Task I.3: [*] (, Amyris) 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

    	 	17

    	HR0011-15-3-0001

    

 

Task Objective: [*]

 

Milestone (Month 12): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

Subtask I.3.1 (Month 10): [*]

 

Task I.4: [*] (, Amyris)

Task Objective: [*]

 

Milestone (Month 18): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Subtask I.4.1 (Month 9): [*]

 

Subtask I.4.2 (Month 12): [*]

 

Subtask I.4.3 (month 15): [*]

 

Task I.5: [*] (, Univ. of Heidelberg) 

Task Objective: [*]

 

Milestone (Month 12): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

Subtask I.5.1 (Month 10): [*]

 

Task I.6: [*] (, Amyris)

Task Objective: [*]

 

Milestone (Month 18): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

    	 	18

    	HR0011-15-3-0001

    

 

Subtask I.6.1 (Month 9): [*]

 

Subtask I.6.2 (Month 12): [*]

 

Subtask I.6.3 (month15): [*]

 

 

MODULE J: [*]

 

Task J.1: [*] (, Amyris)

Task Objective: [*]

 

Milestone (Month 3): [*] 

Deliverables: [*]

 

Subtask J1.1 (Month 2): [*]

 

Subtask J1.2 (Month 3): [*]

 

Milestone (Month 12): [*]

Deliverables: [*]

 

Subtask J1.2 (Month 6): [*]

 

Subtask J1.3 (Month 9): [*]

 

Milestone (Month 18): [*]

Deliverables: [*]

 

Subtask J1.4 (Month 12): [*]

 

Subtask J1.5 (Month 15): [*]

 

Subtask J1.6 (Month 18): [*]

 

Task J.2: [*] (, Amyris).

Task Objective: [*]

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

    	 	19

    	HR0011-15-3-0001

    

 

Milestone (Month 21): [*]

Deliverables: [*]

 

Subtask J2.1 (Month 20): [*]

 

Milestone (Month 24): [*]

Deliverables: [*]

 

Subtask J2.2 (Month 24): [*]

 

Subtask J2.3 (Month 24): [*]

 

Task J.3: [*] (, Amyris)

Task Objective: [*]

 

Milestone (Month 30): [*]

Deliverables: [*]

Subtask J3.1 (Month 27): [*]

 

Subtask J3.2 (Month 30): [*]

 

Subtask J3.3 (Month 30): [*]

 

Milestone (Month 30): [*]

Deliverables: [*]

 

Subtask J3.4 (Month 27): [*]

 

Subtask J3.5 (Month 30): [*]

 

Milestone (Month 33): [*]

Deliverables: [*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

    	 	20

    	HR0011-15-3-0001

    

 

Subtask J3.6 (Month 30): [*]

 

Subtask J3.7 (Month 33): [*]

 

Milestone (Month 36): [*] 

Deliverables: [*] 

Subtask J3.8 (Month 33): [*]

 

Subtask J3.9 (Month 36): [*]

 

Task J.4 (Optional): [*] (, Amyris)

Task Objective: [*]

 

Milestone (12 months): [*]

Deliverables: [*]

 

Subtask J4.1 (Month 3): [*]

 

Subtask J4.2 (Month 6): [*]

 

Subtask J4.3 (Month 6): [*]

 

Subtask J4.4 (Month 12): [*]

 

Milestone (18 months): [*]

Deliverables: [*]

 

Subtask J4.5 (Month 6): [*]

 

Subtask J4.6 (Month 12): [*]

 

Subtask J4.7 (Month 18): [*]

 

Milestone (24 months): [*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

    	 	21

    	HR0011-15-3-0001

    

 

[*]

Deliverables: [*]

 

Subtask J4.8 (Month 21): [*]

 

Subtask J4.9 (Month 24): [*]

 

Subtask J4.10 (Month 24): [*]

 

MODULE K: [*]

 

Task K.1: [*] (, Amyris)

Task Objective: [*]

 

Milestone (Month 6): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Task K.2: [*] (, Amyris)

Task objective: [*]

 

Milestone (Month 12): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Task K.3[*] (, Amyris)

Task objective: [*]

 

Milestone (Month 18): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Task K.4: [*] (, Amyris) 

Task Objective: [*]

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

    	 	22

    	HR0011-15-3-0001

    

 

Milestone (Month 24): [*]

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Milestone (Month 30): [*] 

Metrics/Completion Criteria: [*]

Deliverables: [*]

 

Task L: Biosafety and Biosecurity Planning and Reporting

Task Objective:The research and engineering depicted in this Statement
of Work seeks to make existing capabilities (e.g. genetic modification of microbes to produce commodity chemicals) more efficient
with the intended purpose of speeding the development of Living Foundries. The goal of this research is to make better engineering
tools, and not to produce microbes that may have dual-use potential. As noted in the Performer’s technical proposal, a review
of the research activities identified within this Statement of Work determined that this project will not enable technologies that
are related to human, animal, or plant health. The Performer’s choice of potential chassis or hosts will be made from amongst
the list of microbes that, prior to genetic modification, are designated safely handled in a Biosafety Level 1 facility. Additionally,
the resulting genetically modified organisms have no selective advantage in the environment. The Performer shall demonstrate throughout
the program that all methods and demonstrations of capability comply with national guidance for manipulation of genes and organisms
and follow all guidance for biological safety and biosecurity. Demonstrations and testbeds must meet any applicable regulations
designed to protect human health and the environment promulgated by the Environmental Protection Agency, National Institutes of
Health, or other relevant agencies of the Federal Government. The Performer shall use, store, and destroy biological material in
accordance with all applicable regulations.

 

Deliverable: Include as part of the Monthly Technical Status Reports
an on-going status of Performer efforts to develop and/or carry out Bio-Safety and Security requirements.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

    	 	23

    	HR0011-15-3-0001

    

 

M2K project timelines and milestones

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an
asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

 

     

    	HR0011-15-3-0001

    

 

Attachment 3

 

Total Agreement Funding Plan and Payable Milestones and Corresponding
Payment Schedule

Revision 2

 

Total Agreement Funding Plan

(for informational purposes only)

 

	 	DARPA 

Payment 

Total	Performer 

Contribution 

$	
        Agreement 

Funding

        Grand Total
	
        DARPA 

Share 

        %
	Performer 

Contribution 

%
	Module A Total	$11,267,168 	$1,238,563 	$12,505,727 	90.10%	9.90%
	Module B Total	$4,517,217 	$767,829 	$5,285,046 	85.47%	14.53%
	Module C Total	$1,065,228 	$565,813 	$1,631,041 	65.31%	34.69%
	Module D Total	$2,532,939 	$1,003,490 	$3,536,429 	71.62%	28.38%
	Module E Total	$1,183,490 	$1,939,053 	$3,122,543 	37.90%	62.10%
	Module F Total	$1,054,407 	$767,829 	$1,822,236 	57.86%	42.14%
	Module G Total	DELETED
	Module H Total	$5,895,752 	$3,831,230 	$9,726,982 	60.61%	39.39%
	Module I Total	$1,462,441 	$1,775,450 	$3,237,891 	45.17%	54.83%
	Module J Total	$3,000,887 	$2,517,831 	$5,518,718 	54.38%	45.62%
	Module K Total	$3,180,481 	$1,154,251 	$4,334,731 	73.37%	26.63%
	 	$35,160,011 	$15,561,338 	$50,721,349 	69.32%	30.68%

 

	DARPA Payment Totals by Month
	Month 3	Jan 31 2016	$1,194,797
	Month 6	Apr 30 2016	$2,763,283
	Month 9	Jul 31 2016	$852,072
	Month 12	Oct 31 2016	$6,385,002
	Month 15	Jan 31 2017	$100,567
	Month 18	Apr 30 2017	$5,379,661
	Month 21	Jul 31 2017	$350,130
	Month 24	Oct 31 2017	$5,934,327
	Month 30	Apr 30 2018	$5,262,210
	Month 33	Jul 31 2018	$119,404
	Month 36	Oct 31 2018	$3,429,005
	Month 42	Apr 30 2019	$1,974,919
	Month 42 Option	Apr 30 2019	$85,125
	Month 45	Jul 31 2019	$391,210
	Month 48	Oct 31 2019	$31,256
	Month 48 Option	Oct 31 2019	$907,043
	Baseline	 	$34,167,843
	Option	 	$992,168
	Grand Total 	 	$35,160,011

 

     

    	HR0011-15-3-0001

    

 

Payable Milestones and Corresponding Payment Schedule

Revision 2

 

	MS

        Month
	Task	Metric	Technical

        MS
	Payable MS

        Value
	Technical MS

        Payment
	CLIN/SLIN/

    ACRN
	[*]	[*]	[*]	[*]	[*]	[*]	0001/01/AA
	[*]	[*]	[*]	[*]	[*]	[*]	0001/01/AA
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0001/01/AA
	[*]	[*]	[*]	[*]	[*]	[*]	0001/01/AA
	[*]	[*]	[*]	[*]	[*]	[*]	0001/01/AA
	[*]	[*]	[*]	[*]	[*]	[*]	0001/01/AA
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	0001/01/AA

 

 

[*] Certain portions denoted with an asterisk have been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

     

    	HR0011-15-3-0001

    

 

 

	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0001/01/AA
	[*]	[*]	[*]	[*]	[*]	[*]	0001/01/AA
	[*]	[*]	[*]	[*]	[*]	[*]	0001/01/AA
	[*]	[*]	[*]	[*]	[*]

 

 

[*] Certain portions denoted with an asterisk have been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

 

     

    	HR0011-15-3-0001

    

 

	[*]	[*]	[*]	[*]	[*]	[*]	0001/01/AA
	[*]	[*]	[*]	[*]	[*]	[*]	0001/01/AA
	[*]	[*]	[*]	[*]	[*]	[*]	0001/01/AA
	[*]	[*]	[*]	[*]	[*]	[*]	0001/01/AA
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0001/01/AA
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0001/01/AA
	[*]	[*]	[*]	[*]	[*]

 

 

[*] Certain portions denoted with an asterisk have been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

 

     

    	HR0011-15-3-0001

    

 

 

	[*]	[*]	[*]	[*]	[*]	[*]	0001/01/AA
	[*]	[*]	[*]	[*]	[*]	[*]	0001/01/AA

        0001/02/AB

	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB

 

 

[*] Certain portions denoted with an asterisk have been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

 

     

    	HR0011-15-3-0001

    

 

 

	[*]	[*]	[*]	[*]	[*]	[*]	0001/01/AA

        0001/02/AB

	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB

 

[*] Certain portions denoted with an asterisk have been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

 

     

    	HR0011-15-3-0001

    

 

 

	 	 	[*]	 	 	 	 
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]

 

 

[*] Certain portions denoted with an asterisk have been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

 

     

    	HR0011-15-3-0001

    

 

 

	[*]	[*]	[*]	[*]	[*]	 	 
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]

 

[*] Certain portions denoted with an asterisk have been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

 

     

    	HR0011-15-3-0001

    

 

 

	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]

 

[*] Certain portions denoted with an asterisk have been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

     

    	HR0011-15-3-0001

    

 

 

	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0001/02/AB

 

[*] Certain portions denoted with an asterisk have been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

 

     

    	HR0011-15-3-0001

    

 

	 	 	[*]	 	 	 	 
	[*]	[*]	[*]	[*]	[*]	[*]	
        0001/02/AB

        (partialy

        funded

        $431,041)

	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]	[*]	 

 

[*] Certain portions denoted with an asterisk have been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

     

    	HR0011-15-3-0001

    

 

 

	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]	[*]	 

 

 

[*] Certain portions denoted with an asterisk have been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

 

     

    	HR0011-15-3-0001

    

 

	[*]	[*]	[*]	[*]	[*]	[*]	 
	 	 	Baseline Costs	 	 	$34,167,843	 
	 	 	Option Costs	 	 	$992,168	 
	 	 	TOTAL	 	 	$35,160,011	 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

 

     

    	HR0011-15-3-0001

    

 

Attachment 5

 

List of Intellectual Property Assertions by the Performer

 

 

The Performer reserves the right to add to or modify this Attachment
5 (including Tables 1, 2, 3, 4, 5, 6, 7 and 8). Note that divisional patents and patent applications are not listed in this Attachment
5

 

Table 1 lists technical data and computer software of Amyris, Inc.
that is intended to be generated, developed and/or delivered as a result of the work proposed for the Program, for which the Government
will acquire Limited Rights.

 

	 Table 1.
	Technical Data and Computer 

Software to be Furnished with 

Restrictions	 	Basis for Assertion	Name of Person 

Asserting 

Restrictions
	[*]	Limited Rights	[*]	Amyris, Inc.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

This page contains proprietary information of Amyris, Inc. that is provided
for purposes of review and evaluation only on a need-to-know basis within the Government. It should not be released to persons
outside the Government.

 

    	 	1

    	HR0011-15-3-0001

    

 

 

	[*]	Limited Rights	[*]	Amyris, Inc.
	[*]	Limited Rights	[*]	Amyris, Inc.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

This page contains proprietary information of Amyris, Inc.
that is provided for purposes of review and evaluation only on a need-to-know basis within the Government. It should not be released
to persons outside the Government.

 

    	 	2

    	HR0011-15-3-0001

    

 

Table 2 provides an exemplary, non-limiting list of patents and
patent applications, pending or issued as of September 11, 2015, of Amyris, Inc., the Inventions of which may be used in the performance
of the Program but to which the Government shall have no rights because they existed prior to the Effective Date:

 

Table 2.

 

	Title	Application No.	
        Patent No.

        (Publication No.)

	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

This page contains proprietary information of Amyris, Inc.
that is provided for purposes of review and evaluation only on a need-to-know basis within the Government. It should not be released
to persons outside the Government.

 

    	 	3

    	HR0011-15-3-0001

    

 

 

	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

This page contains proprietary information of Amyris, Inc.
that is provided for purposes of review and evaluation only on a need-to-know basis within the Government. It should not be released
to persons outside the Government.

 

    	 	4

    	HR0011-15-3-0001

    

 

 

Table 3 lists technical data and computer software of Arzeda Corp.
that is intended to be generated, developed and/or delivered as a result of the work proposed for the Program, for which the Government
will acquire Limited Rights.

 

	 Table 3.
	Technical Data and Computer

 Software to be Furnished with 

Restrictions	 	Basis for Assertion	Name of Person 

Asserting 

Restrictions
	[*] 	Limited Rights	[*] 	
        Arzeda Corp.

         

         

	[*] 	Limited Rights	[*] 	Arzeda Corp.
	[*] 	
        Limited Rights

         

         

         

         

         

         

         

         

         

         

         

        Government

        Purpose Rights

        (applicable during

        TIA Period of

        Performance)
	[*] 	Arzeda Corp.

 

 

 

 

 

This page contains proprietary information of Amyris, Inc.
that is provided for purposes of review and evaluation only on a need-to-know basis within the Government. It should not be released
to persons outside the Government.

 

    	 	5

    	HR0011-15-3-0001

    

 

 

 

	[*]	Limited
    Rights	[*]	Arzeda Corp.

         

         

         

         

	[*]	Limited Rights	[*]	Arzeda Corp.
	[*]	
        Government

        Purpose Rights
	[*]	Arzeda Corp.

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

 

 

 

 

 

 

 

 

 

This page contains proprietary information of Amyris, Inc.
that is provided for purposes of review and evaluation only on a need-to-know basis within the Government. It should not be released
to persons outside the Government.

 

    	 	6

    	HR0011-15-3-0001

    

 

 

	[*]	Limited Rights	[*]	Arzeda Corp.

 

 

Table 4 provides an exemplary, non-limiting list of patents and
patent applications, pending or issued as of November 1, 2015, of Arzeda Corp., the Inventions of which may be used in the performance
of the Program but to which the Government shall have no rights because they existed prior to the Effective Date:

 

Table 4.

 

	Title	Application No.	
        Patent No.

        (Publication No.)

	[*]	[*]	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	[*]	[*]
	[*]	[*]	[*]
	[*]	[*]	 
	[*]	[*]	 
	[*]	[*]	[*]

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions

 

 

 

 

 

 

 

This page contains proprietary information of Amyris, Inc.
that is provided for purposes of review and evaluation only on a need-to-know basis within the Government. It should not be released
to persons outside the Government.

 

    	 	7

    	HR0011-15-3-0001

    

 

 

Table 5 lists technical data and/or computer software of Agilent
Technologies, Inc. that is intended to be used in the performance of the M2K Program, which was generated or developed at Agilent’s
private expense for which the Government will acquire Government Purpose Rights.

 

	Table 5
	Technical Data and Computer 

Software to be Furnished with 

Restrictions	Restrictions	Basis for Assertion	Name of Person 

Asserting 

Restrictions
	[*]	Government Purpose Rights	[*]	
        Agilent

        Technologies, Inc.

	[*]	Government Purpose Rights	[*]	
        Agilent

        Technologies, Inc.

 

Table 6 provides an exemplary, non-limiting list of patents and
patent applications, pending or issued as of September 11, 2015, of Agilent Technologies, Inc., the Inventions of which may be
used in the performance of the Program but to which the Government shall have no rights because they existed prior to the Effective
Date:

 

Table 6.

 

	Title	Application No.	
        Patent No.

        (Publication No.)

	[*]	[*]	 
	[*]	[*]	 
	[*]	[*]	 
	[*]	[*]	 
	[*]	[*]	 
	[*]	[*]	 
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions

 

 

 

 

This page contains proprietary information of Amyris, Inc.
that is provided for purposes of review and evaluation only on a need-to-know basis within the Government. It should not be released
to persons outside the Government.

 

    	 	8

    	HR0011-15-3-0001

    

 

 

 

Table 7 lists technical data and computer software of Ruprecht-Karls-Universität
Heidelberg, Professor Oliver Trapp, and/or Trapp ChemTech Inc. that is intended to be generated, developed and/or delivered as
a result of the work proposed for the Program, for which the Government will acquire Limited Rights.

 

	Table 7.
	Technical Data and Computer 

Software to be Furnished with 

Restrictions	Restrictions	Basis for Assertion	Name of Person

                                                                                Asserting 

Restrictions

	[*]	Limited Rights	[*]	
        Trapp ChemTech,

        Inc.

 

 

 

 

Table 8 provides an exemplary, non-limiting list of patents and
patent applications, pending or issued as of September 11, 2015, of Ruprecht-Karls-Universität Heidelberg, Professor Oliver
Trapp, and/or Trapp ChemTech Inc., the Inventions of which may be used in the performance of the Program but to which the Government
shall have no rights because they existed prior to the Effective Date:

 

	Title	Application No.	
        Patent No.

        (Publication No.)

	[*]	[*]	 
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]

 

 

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions

 

 

 

 

 

This page contains proprietary information of Amyris, Inc.
that is provided for purposes of review and evaluation only on a need-to-know basis within the Government. It should not be released
to persons outside the Government.

 

    	 	9

    	HR0011-15-3-0001

    

 

Attachment 6

List of Property Greater than $5,000

 

	Module	Material/Equipment	Units	Unit $	Total Cost
	E	[*]	1	$237,177	$237,177
	E	[*]	4	$4978	$19,912
	E	[*]	1	$108,405	$108,405
	E	[*]	1	$321,849	$321,849
	E	[*]	2	$60,061	$120,122
	E	[*]	1	$363,759	$363,759
	H	[*]	2	$787,291.50	$1,574,583
	H	[*]	1	$150,431	$150,431
	H	[*]	1	$495,970	$495,970
	H	[*]	1	$399,344	$399,344
	H	[*]	1	$5,411	$5,411
	H	[*]	1	$33,848	$33,848
	H	[*]	1	$26,919	$26,919
	H	[*]	1	$18,456	$18,456
	H	[*]	1	$61,923	$61,923
	H	[*]	1	$14,690	$14,690
	H	[*]	2	$14,358	$28,716
	I	[*]	1	$111,991	$111,991
	I	[*]	1	$129,221	$129,221
	I	[*]	1	$766,409	$766,409
	I	[*]	1	$93,000	$93,000
	I	[*]	2	$12,050	$24,100
	J	[*]	1	$190,859	$190,859
	J	[*]	1	$123,407	$123,407
	J	[*]	3	$190,859	$572,577
	J	[*]	3	$123,407	$370,221
	J	[*]	1	$150,000	$150,000
	K	[*]	1	$232,690	$232,690
	K	[*]	1	$30,000	$30,000
	K	[*]	1	$8,477	$8,477

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

 

 

This page contains proprietary information of Amyris, Inc.
that is provided for purposes of review and evaluation only on a need-to-know basis within the Government. It should not be released
to persons outside the Government.

 

10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}]]